Home The Word Brain Fast Track My Amedeo FAQ About Flying Publisher   

Fast Track

Ear2MemoryFree App | Free PDF | Web
Learning languages on your smartphone
By BSK

Free Abstracts

  Liver Diseases

  Free Subscription


Articles published in J Hepatol

Retrieve available abstracts of 452 articles:
HTML format
Text format



Single Articles


    April 2017
  1. SEIDEL RA, Claudel T, Schleser FA, Ojha NK, et al
    Impact of higher-order heme degradation products on hepatic function and hemodynamics.
    J Hepatol. 2017 Apr 12. pii: S0168-8278(17)30208.
    PubMed     Text format     Abstract available


  2. KWO PY, Poordad F, Asatryan A, Wang S, et al
    Glecaprevir and Pibrentasvir Yield High response Rates in Patients with HCV Genotype 1-6 without Cirrhosis.
    J Hepatol. 2017 Apr 12. pii: S0168-8278(17)30211.
    PubMed     Text format     Abstract available


  3. HASSON H, Merli M, Messina E, Bhoori S, et al
    Occurrence of hepatocellular carcinoma in HIV/HCV co-infected patients treated with direct-acting antivirals.
    J Hepatol. 2017 Apr 11. pii: S0168-8278(17)30203.
    PubMed     Text format     Abstract available


  4. TAPPER EB, Sengupta N
    Testing for elevated liver enzymes: central to clinical Hepatology but in need of more data.
    J Hepatol. 2017 Apr 6. pii: S0168-8278(17)30199.
    PubMed     Text format    


    March 2017
  5. KIM JY, Park KJ, Hwang JY, Kim GH, et al
    Activating Transcription Factor 3 Is a Target Molecule Linking Hepatic Steatosis to Impaired Glucose Homeostasis.
    J Hepatol. 2017 Mar 29. pii: S0168-8278(17)30187.
    PubMed     Text format     Abstract available


  6. QURINO L, Massimo R, Jan L
    Proposal of a novel MELD exception point system for hepatocellular carcinoma: Dynamics better than tumor characteristics?
    J Hepatol. 2017 Mar 24. pii: S0168-8278(17)30180.
    PubMed     Text format    


  7. BHAT M, Ghali P, Bilodeau M
    Reply to: "Proposal of a novel MELD exception point system for hepatocellular carcinoma: Dynamics better than tumor characteristics?"
    J Hepatol. 2017 Mar 24. pii: S0168-8278(17)30183.
    PubMed     Text format    


  8. PREZIOSI ME, Singh S, Valore EV, Jung CL, et al
    Mice lacking liver-specific beta-catenin develop steatohepatitis and fibrosis after iron overload.
    J Hepatol. 2017 Mar 21. pii: S0168-8278(17)30146.
    PubMed     Text format     Abstract available


  9. BERTUCCIO P, Turati F, Carioli G, Rodriguez T, et al
    Global Trends and Predictions in Hepatocellular Carcinoma Mortality.
    J Hepatol. 2017 Mar 20. pii: S0168-8278(17)30145.
    PubMed     Text format     Abstract available


  10. URBAN TJ, Nicoletti P, Chalasani N, Serrano J, et al
    Minocycline Hepatotoxicity: Clinical characterization and identification of HLA-B * 35:02 as a risk factor.
    J Hepatol. 2017 Mar 17. pii: S0168-8278(17)30144.
    PubMed     Text format     Abstract available


  11. HUANG A, Zhao X, Yang XR, Li FQ, et al
    Circumventing intratumoral heterogeneity to identify potential therapeutic targets in hepatocellular carcinoma.
    J Hepatol. 2017 Mar 17. pii: S0168-8278(17)30139.
    PubMed     Text format     Abstract available


  12. VILARINHO S, Erson-Omay Z, Mitchell-Richards K, Cha C, et al
    Exome Analysis of the Evolutionary Path of Hepatocellular Adenoma-Carcinoma Transition, Vascular Invasion and Brain Dissemination.
    J Hepatol. 2017 Mar 17. pii: S0168-8278(17)30143.
    PubMed     Text format     Abstract available


  13. PATOURAUX S, Rousseau D, Bonnafous S, Lebeaupin C, et al
    CD44 is a key player in non-alcoholic steatohepatitis.
    J Hepatol. 2017 Mar 16. pii: S0168-8278(17)30137.
    PubMed     Text format     Abstract available


  14. TAI WT, Cheng AL, Shiau CW, Huang HP, et al
    Erratum to: Corrigendum to "Signal transducer and activator of transcription 3 is a major kinase-independent target of sorafenib in hepatocellular carcinoma".
    J Hepatol. 2017 Mar 13. pii: S0168-8278(17)30118.
    PubMed     Text format    


  15. BRUIX J, Reig M, Sangro B
    Assessment of treatment efficacy in hepatocellular carcinoma: response rate, delay in progression or none of them.
    J Hepatol. 2017 Mar 8. pii: S0168-8278(17)30133.
    PubMed     Text format    


  16. BESTE LA, Green PK, Berry K, Kogut MJ, et al
    Effectiveness of hepatitis c antiviral treatment in a USA cohort of veteran patients with hepatocellular carcinoma.
    J Hepatol. 2017 Mar 3. pii: S0168-8278(17)30126.
    PubMed     Text format     Abstract available


  17. TACKE F
    Targeting hepatic macrophages to treat liver diseases.
    J Hepatol. 2017 Mar 3. pii: S0168-8278(17)30125.
    PubMed     Text format     Abstract available


  18. JULICH-HAERTEL H, Urban SK, Krawczyk M, Willms A, et al
    Cancer-associated circulating large extracellular vesicles in cholangiocarcinoma and hepatocellular carcinoma.
    J Hepatol. 2017 Mar 3. pii: S0168-8278(17)30123.
    PubMed     Text format     Abstract available


  19. DE MATTOS AZ, de Mattos AA
    The Baveno VI criteria to identify patients not requiring endoscopic surveillance for esophageal varices - should we use it?
    J Hepatol. 2017 Mar 2. pii: S0168-8278(17)30130.
    PubMed     Text format    


    February 2017
  20. SAPISOCHIN G, Barry A, Doherty M, Fischer S, et al
    Stereotactic body radiotherapy versus TACE or RFA as a bridge to transplant in patients with hepatocellular carcinoma. An intention-to-treat analysis.
    J Hepatol. 2017 Feb 28. pii: S0168-8278(17)30119.
    PubMed     Text format     Abstract available


  21. ORNTOFT NW, Munk OL, Frisch K, Ott P, et al
    Hepatobiliary transport kinetics of the conjugated bile acid tracer 11C-CSar quantified in healthy humans and patients by Positrion Emission Tomography (PET).
    J Hepatol. 2017 Feb 26. pii: S0168-8278(17)30120.
    PubMed     Text format     Abstract available


  22. OBA A, Shimada S, Akiyama Y, Nishikawaji T, et al
    ARID2 modulates DNA damage response in human hepatocellular carcinoma cells.
    J Hepatol. 2017 Feb 23. pii: S0168-8278(17)30003.
    PubMed     Text format     Abstract available


  23. LUUKKONEN PK, Zhou Y, Nidhina Haridas PA, Dwivedi OP, et al
    Impaired hepatic lipid synthesis from polyunsaturated fatty acids in TM6SF2 E167K variant carriers with NAFLD.
    J Hepatol. 2017 Feb 21. pii: S0168-8278(17)30109.
    PubMed     Text format     Abstract available


  24. MONTAGNESE S, De Rui M, Angeli P, Amodio P, et al
    Reply to: Tools and tactics for improving diagnosis of hepatic encephalopathy.
    J Hepatol. 2017 Feb 16. pii: S0168-8278(17)30102.
    PubMed     Text format    


  25. OLESEN SS, Jackson CD, Morgan MY
    Tools and tactics for improving diagnosis of hepatic encephalopathy.
    J Hepatol. 2017 Feb 16. pii: S0168-8278(17)30103.
    PubMed     Text format    


  26. BLERIOT C, Lecuit M
    RIPK1, a key survival factor for hepatocytes.
    J Hepatol. 2017 Feb 16. pii: S0168-8278(17)30104.
    PubMed     Text format    


  27. SINHA R, Lockman KA, Mallawaarachchi N, Robertson M, et al
    Carvedilol use is associated with improved survival in patients with liver cirrhosis and ascites.
    J Hepatol. 2017 Feb 14. pii: S0168-8278(17)30073.
    PubMed     Text format     Abstract available


  28. BERZIGOTTI A
    Non invasive evaluation of portal hypertension using ultrasound elastography.
    J Hepatol. 2017 Feb 13. pii: S0168-8278(17)30071.
    PubMed     Text format     Abstract available


  29. DRESCHER HK, Schippers A, Clahsen T, Sahin H, et al
    beta7-Integrin and MAdCAM-1 play opposing roles during the development of non-alcoholic steatohepatitis.
    J Hepatol. 2017 Feb 9. pii: S0168-8278(17)30065.
    PubMed     Text format     Abstract available


  30. YAMASHITA S, Shindoh J, Mizuno T, Chun YS, et al
    Hepatic Atrophy Following Preoperative Chemotherapy Predicts Hepatic Insufficiency after Resection of Colorectal Liver Metastases.
    J Hepatol. 2017 Feb 9. pii: S0168-8278(17)30068.
    PubMed     Text format     Abstract available


  31. WU H, Yao S, Zhang S, Wang JR, et al
    Elevated expression of Erbin destabilizes ERalpha protein and promotes tumorigenesis in hepatocellular carcinoma.
    J Hepatol. 2017 Feb 9. pii: S0168-8278(17)30067.
    PubMed     Text format     Abstract available


  32. CABIBBO G, Petta S, Barbara M, Attardo S, et al
    Hepatic Decompensation is the Major Driver of Death In HCV-infected cirrhotic patients with successfully treated early hepatocellular carcinoma.
    J Hepatol. 2017 Feb 9. pii: S0168-8278(17)30070.
    PubMed     Text format     Abstract available


  33. ZHOU M, Luo J, Chen M, Yang H, et al
    Mice species-specific control of hepatocarcinogenesis and metabolism by FGF19/FGF15.
    J Hepatol. 2017 Feb 8. pii: S0168-8278(17)30062.
    PubMed     Text format     Abstract available


  34. DASARATHY S, Merli M
    Reply to: Myokines: a promising therapeutic target for hepatic encephalopathy.
    J Hepatol. 2017 Feb 6. pii: S0168-8278(17)30058.
    PubMed     Text format    


  35. YANG C, Luo AL
    Myokines: a promising therapeutic target for hepaticencephalopathy.
    J Hepatol. 2017 Feb 3. pii: S0168-8278(17)30057.
    PubMed     Text format    


  36. PRENNER S, VanWagner LB, Flamm SL, Salem R, et al
    Hepatocellular Carcinoma Decreases the Chance of Successful Hepatitis C Virus Therapy with Direct-Acting Antivirals.
    J Hepatol. 2017 Feb 1. pii: S0168-8278(17)30053.
    PubMed     Text format     Abstract available


    January 2017
  37. MOEINI A, Sia D, Zhang Z, Camprecios G, et al
    Mixed hepatocellular-cholangiocarcinoma tumors: cholangiolocellular carcinoma is a distinct molecular entity.
    J Hepatol. 2017 Jan 23. pii: S0168-8278(17)30014.
    PubMed     Text format     Abstract available


  38. HEIER EC, Meier A, Julich-Haertel H, Djudjaj S, et al
    Murine CD103+ dendritic cells protect against steatosis progression towards steatohepatitis.
    J Hepatol. 2017 Jan 17. pii: S0168-8278(17)30012.
    PubMed     Text format     Abstract available


  39. FILLIOL A, Piquet-Pellorce C, Raguenes-Nicol C, Dion S, et al
    RIPK1 protects hepatocytes from Kupffer cells-mediated TNF-induced apoptosis in mouse models of PAMP-induced hepatitis.
    J Hepatol. 2017 Jan 11. pii: S0168-8278(17)30009.
    PubMed     Text format     Abstract available


  40. BOURSIER J, de Ledinghen V, Leroy V, Anty R, et al
    A stepwise algorithm using a at-a-glance first-line test for the non-invasive diagnosis of advanced liver fibrosis and cirrhosis.
    J Hepatol. 2017 Jan 11. pii: S0168-8278(17)30007.
    PubMed     Text format     Abstract available


  41. GOTO K, Kato N
    Histone deacetylase inhibitor for the treatment of hepatocellular carcinoma: chemoimmunotherapeutic perspective and prospects.
    J Hepatol. 2017 Jan 9. pii: S0168-8278(17)30001.
    PubMed     Text format    


  42. HANLEY J, Kumar Dhar D, Mazzacuva F, Fiadeiro R, et al
    Vps33b is Crucial for Structural and Functional Hepatocyte Polarity.
    J Hepatol. 2017 Jan 9. pii: S0168-8278(17)30005.
    PubMed     Text format     Abstract available


  43. BITZER M, Salih HR
    Reply to "Histone deacetylase inhibitor for the treatment of hepatocellular carcinoma: chemoimmunotherapeutic perspective and prospects".
    J Hepatol. 2017 Jan 9. pii: S0168-8278(17)30004.
    PubMed     Text format    


  44. TAI WT, Cheng AL, Shiau CW, Huang HP, et al
    Corrigendum to "Signal transducer and activator of transcription 3 is a major kinase-independent target of sorafenib in hepatocellular carcinoma".
    J Hepatol. 2017 Jan 6. pii: S0168-8278(16)30712.
    PubMed     Text format    


  45. YE D, Yang K, Zang S, Lin Z, et al
    Corrigendum to "Lipocalin-2 mediates non-alcoholic steatohepatitis by promoting neutrophil-macrophage crosstalk via the induction of CXCR2".
    J Hepatol. 2017 Jan 5. pii: S0168-8278(16)30711.
    PubMed     Text format    


  46. EKSTEEN B, Heatherington J, Oshiomogo J, Panaccione R, et al
    Retraction notice to: PS124-Efficacy and Safety of Induction Dosing of Vedolizumab for Reducing Biliary Inflammation in Primary Sclerosing Cholangitis (PSC) in Individuals with Inflammatory Bowel Disease [J Hepatol 64 (2016) S199].
    J Hepatol. 2017;66:254.
    PubMed     Text format    


    December 2016
  47. CRUZ-LEMINI M, Altamirano J, Ndugga N, Abraldes JG, et al
    Reply to: Heavy daily alcohol intake at the population level predicts the weight of alcohol in cirrhosis burden worldwide: methodological issues of confounding and prediction models.
    J Hepatol. 2016 Dec 30. pii: S0168-8278(16)30756.
    PubMed     Text format    


  48. LEBOSSE F, Testoni B, Fresquet J, Facchetti F, et al
    Intrahepatic innate immune response pathways are down-regulated in untreated chronic hepatitis B.
    J Hepatol. 2016 Dec 30. pii: S0168-8278(16)30757.
    PubMed     Text format     Abstract available


  49. AYUBI E, Safiri S, Sani M, Khazaei S, et al
    Heavy daily alcohol intake at the population level predicts the weight of alcohol in cirrhosis burden worldwide: methodological issues of confounding and prediction models.
    J Hepatol. 2016 Dec 30. pii: S0168-8278(16)30758.
    PubMed     Text format    


  50. WEISS E, Rautou PE, Fasseu M, Giabicani M, et al
    Type I interferon signaling in systemic immune cells from patients with alcoholic cirrhosis and its association with outcome.
    J Hepatol. 2016 Dec 28. pii: S0168-8278(16)30741.
    PubMed     Text format     Abstract available


  51. SOLTYS KA, Setoyama K, Tafaleng EN, Soto Gutierrez A, et al
    Host conditioning and rejection monitoring in hepatocyte transplantation in humans.
    J Hepatol. 2016 Dec 24. pii: S0168-8278(16)30750.
    PubMed     Text format     Abstract available


  52. WU H, Zhang T, Pan F, Steer CJ, et al
    MicroRNA-206 prevents hepatosteatosis and hyperglycemia by facilitating insulin signaling and impairing lipogenesis.
    J Hepatol. 2016 Dec 23. pii: S0168-8278(16)30749.
    PubMed     Text format     Abstract available


  53. SPRINZL MF, Galle PR
    Current progress in immunotherapy of hepatocellular carcinoma.
    J Hepatol. 2016 Dec 20. pii: S0168-8278(16)30742.
    PubMed     Text format    


  54. SCHWABL P, Hambruch E, Seeland BA, Hayden H, et al
    The FXR agonist PX20606 ameliorates portal hypertension by targeting vascular remodelling and sinusoidal dysfunction.
    J Hepatol. 2016 Dec 16. pii: S0168-8278(16)30710.
    PubMed     Text format     Abstract available


  55. ARROYO V, Moreau R
    Diagnosis and prognosis of acute on chronic liver failure (ACLF) in cirrhosis.
    J Hepatol. 2016 Dec 15. pii: S0168-8278(16)30577.
    PubMed     Text format    


  56. MANGIA A, Susser S, Piazzolla V, Agostinacchio E, et al
    Sofosbuvir and Ribavirin for genotype 2 HCV infected patients with cirrhosis: a real life experience.
    J Hepatol. 2016 Dec 10. pii: S0168-8278(16)30707.
    PubMed     Text format     Abstract available


  57. KOLLY P, Dufour JF
    Patients with hepatocellular carcinoma: Your address matters!
    J Hepatol. 2016 Dec 10. pii: S0168-8278(16)30703.
    PubMed     Text format    


  58. NI Y, Urban S
    Stem cell-derived hepatocytes: a promising novel tool to study Hepatitis B Virus infection.
    J Hepatol. 2016 Dec 10. pii: S0168-8278(16)30704.
    PubMed     Text format    


  59. SCHWINGE D, von Haxthausen F, Quaas A, Carambia A, et al
    Dysfunction of hepatic regulatory T cells in experimental sclerosing cholangitis is related with IL-12 signaling.
    J Hepatol. 2016 Dec 10. pii: S0168-8278(16)30705.
    PubMed     Text format     Abstract available


  60. MONTAGNESE S, De Rui M, Angeli P, Amodio P, et al
    Neuropsychiatric Performance in Patients with Cirrhosis: Who is "Normal"?
    J Hepatol. 2016 Dec 3. pii: S0168-8278(16)30698.
    PubMed     Text format     Abstract available


    November 2016
  61. LE GUEN V, Judor JP, Boeffard F, Gauttier V, et al
    Alloantigen gene transfer to hepatocytes promotes tolerance to pancreatic islet graft by inducing CD8+ regulatory T cells.
    J Hepatol. 2016 Nov 30. pii: S0168-8278(16)30696.
    PubMed     Text format     Abstract available


  62. DEZSO K, Rokusz A, Bugyik E, Szucs A, et al
    Human liver regeneration in advanced cirrhosis is organized by the portal tree.
    J Hepatol. 2016 Nov 29. pii: S0168-8278(16)30690.
    PubMed     Text format     Abstract available


  63. KYRANA E, Dhawan A
    Minimal hepatic encephalopathy in children, uncommon or unrecognised? -Time to act.
    J Hepatol. 2016 Nov 28. pii: S0168-8278(16)30694.
    PubMed     Text format    


  64. NOTARPAOLO A, Layese R, Magistri P, Gambato M, et al
    Validation of the AFP model as a predictor of HCC recurrence in patients with viral hepatitis-related cirrhosis who had received a liver transplant for HCC.
    J Hepatol. 2016 Nov 26. pii: S0168-8278(16)30688.
    PubMed     Text format     Abstract available


  65. PINATO DJ, Yen C, Sharma R
    Reply to comments by Chan et. al on "The ALBI grade provides objective hepatic reserve estimation across each BCLC stage of hepatocellular carcinoma".
    J Hepatol. 2016 Nov 24. pii: S0168-8278(16)30684.
    PubMed     Text format    


  66. W H CHAN A, H W Leung H, C N Chong C, Chan SL, et al
    Comments on "The ALBI grade provides objective hepatic reserve estimation across each BCLC stage of hepatocellular carcinoma".
    J Hepatol. 2016 Nov 24. pii: S0168-8278(16)30681.
    PubMed     Text format    


  67. CENI E, Mello T, Polvani S, Vasseur-Cognet M, et al
    The orphan nuclear receptor COUP-TFII coordinates hypoxia-independent proangiogenic responses in hepatic stellate cells.
    J Hepatol. 2016 Nov 17. pii: S0168-8278(16)30650.
    PubMed     Text format     Abstract available


  68. REIBERGER T, Mandorfer M
    Beta adrenergic blockade and decompensated cirrhosis.
    J Hepatol. 2016 Nov 15. pii: S0168-8278(16)30647.
    PubMed     Text format     Abstract available


  69. TSAI PC, Huang CF, Yu ML
    Unexpected early tumor recurrence in patients with hepatitis C virus -related hepatocellular carcinoma undergoing interferon-free therapy: issue of tie interval between HCC treatment and antiviral therapy.
    J Hepatol. 2016 Nov 10. pii: S0168-8278(16)30646.
    PubMed     Text format    


  70. JANJUA NZ, Chong M, Kuo M, Woods R, et al
    Long-term effect of sustained virological response on hepatocellular carcinoma in patients with hepatitis C in Canada.
    J Hepatol. 2016 Nov 3. pii: S0168-8278(16)30637.
    PubMed     Text format     Abstract available


  71. DUFFY AG, Ulahannan SV, Makorova-Rusher O, Rahma O, et al
    Tremelimumab in Combination with Ablation in Patients with Advanced Hepatocellular Carcinoma.
    J Hepatol. 2016 Nov 2. pii: S0168-8278(16)30638.
    PubMed     Text format     Abstract available


  72. SRIVASTAVA A, Chaturvedi S, Gupta RK, Malik R, et al
    Minimal hepatic encephalopathy in children with chronic liver disease: prevalence, pathogenesis and magnetic resonance-based diagnosis.
    J Hepatol. 2016 Nov 1. pii: S0168-8278(16)30620.
    PubMed     Text format     Abstract available


    October 2016
  73. MUKHOPADHYAY P, Horvath B, Rajesh M, Varga ZV, et al
    PARP inhibition protects against alcoholic and nonalcoholic steatohepatitis.
    J Hepatol. 2016 Oct 28. pii: S0168-8278(16)30617.
    PubMed     Text format     Abstract available


  74. WANNHOFF A, Friedrich K, Gotthardt DN
    Reduced influence of procoagulant changes on survival in patients with advanced cirrhosis.
    J Hepatol. 2016 Oct 24. pii: S0168-8278(16)30583.
    PubMed     Text format    


  75. VAN DER MEER AJ, Feld JJ, Hofer H, Almasio PL, et al
    Risk of cirrhosis-related complications in patients with advanced fibrosis following hepatitis C virus eradication.
    J Hepatol. 2016 Oct 22. pii: S0168-8278(16)30582.
    PubMed     Text format     Abstract available


  76. GOUTTE N, Sogni P, Bendersky N, Barbare JC, et al
    Geographical variations in incidence, management and survival of hepatocellular carcinoma in a Western country.
    J Hepatol. 2016 Oct 20. pii: S0168-8278(16)30580.
    PubMed     Text format     Abstract available


  77. POTZE W, Sanyal AJ, Lisman T
    How to assess hemostatic capacity in patients with cirrhosis?
    J Hepatol. 2016 Oct 18. pii: S0168-8278(16)30576.
    PubMed     Text format    


  78. BHAT M, Ghali P, Dupont B, Hilzenrat R, et al
    Proposal of a Novel MELD Exception Point System for Hepatocellular Carcinoma based on Tumor Characteristics and Dynamics.
    J Hepatol. 2016 Oct 14. pii: S0168-8278(16)30571.
    PubMed     Text format     Abstract available


  79. XIA Y, Carpentier A, Cheng X, Block PD, et al
    Human stem cell-derived hepatocytes as a model for hepatitis B virus infection, spreading and virus-host interactions.
    J Hepatol. 2016 Oct 13. pii: S0168-8278(16)30572.
    PubMed     Text format     Abstract available


  80. FURUTA M, Ueno M, Fujimoto A, Hayami S, et al
    Whole genome sequencing discriminate hepatocellular carcinoma with intrahepatic metastasis from multicentric tumors.
    J Hepatol. 2016 Oct 11. pii: S0168-8278(16)30561.
    PubMed     Text format     Abstract available


  81. RICKE J, Seidensticker M
    Molecular imaging and liver function assessment by hepatobiliary MRI.
    J Hepatol. 2016 Oct 8. pii: S0168-8278(16)30566.
    PubMed     Text format    


    September 2016
  82. CHAYANUPATKUL M, Omino R, Mittal S, Kramer JR, et al
    Hepatocellular carcinoma in the absence of cirrhosis in patients with chronic hepatitis B virus infection.
    J Hepatol. 2016 Sep 28. pii: S0168-8278(16)30540.
    PubMed     Text format     Abstract available


  83. SHIN WJ, Song JG, Jun IG, Moon YJ, et al
    Effect of ventriculo-arterial coupling on transplant outcomes in cirrhotics: Analysis of pressure-volume curve relations.
    J Hepatol. 2016 Sep 26. pii: S0168-8278(16)30536.
    PubMed     Text format     Abstract available


  84. PINATO DJ, Sharma R, Allara E, Yen C, et al
    The ALBI grade provides objective hepatic reserve estimation across each BCLC stage of hepatocellular carcinoma.
    J Hepatol. 2016 Sep 24. pii: S0168-8278(16)30535.
    PubMed     Text format     Abstract available


  85. FELIPO V, Montagnese S
    A rare and revealing glimpse of the cerebrospinal fluid of patients with hepatic encephalopathy.
    J Hepatol. 2016 Sep 24. pii: S0168-8278(16)30538.
    PubMed     Text format    


  86. VITALE A, Peck-Radosavljevic M, Giannini EG, Vibert E, et al
    Personalized Treatment of Patients with very Early Hepatocellular Carcinoma.
    J Hepatol. 2016 Sep 24. pii: S0168-8278(16)30539.
    PubMed     Text format     Abstract available


  87. VENKATESH SK, Loomba R
    Editorial: Non-invasive estimation of HVPG by combined structural and hemodynamic evaluation of portal hypertension using quantitative magnetic resonance imaging.
    J Hepatol. 2016 Sep 20. pii: S0168-8278(16)30509.
    PubMed     Text format    


  88. DUCHE M, Ducot B, Ackermann O, Guerin F, et al
    Portal hypertension in children: High-risk varices, primary prophylaxis and consequences of bleeding.
    J Hepatol. 2016 Sep 20. pii: S0168-8278(16)30507.
    PubMed     Text format     Abstract available


  89. AHN SJ, Lee JM, Lee DH, Lee SM, et al
    Real-time US-CT/MR Fusion Imaging for Percutaneous Radiofrequency Ablation of Hepatocellular Carcinoma.
    J Hepatol. 2016 Sep 17. pii: S0168-8278(16)30504.
    PubMed     Text format     Abstract available


  90. KOO BK, Kim D, Joo SK, Kim JH, et al
    Sarcopenia is an independent risk factor for non-alcoholic steatohepatitis and significant fibrosis.
    J Hepatol. 2016 Sep 3. pii: S0168-8278(16)30484.
    PubMed     Text format     Abstract available


    August 2016
  91. ROMBOUTS K, Bemeur C, Rose CF
    Targeting the muscle for the treatment and prevention of hepatic encephalopathy.
    J Hepatol. 2016 Aug 30. pii: S0168-8278(16)30474.
    PubMed     Text format    


  92. WAZIRY R, Grebely J, Amin J, Alavi M, et al
    Trends in hepatocellular carcinoma among people with HBV or HCV notification in Australia (2000-2014).
    J Hepatol. 2016 Aug 25. pii: S0168-8278(16)30442.
    PubMed     Text format     Abstract available


  93. FERNANDEZ J, Bert F, Nicolas-Chanoine MH
    The Challenges of Multidrug Resistance in Hepatology.
    J Hepatol. 2016 Aug 17. pii: S0168-8278(16)30431.
    PubMed     Text format     Abstract available


  94. BRITO-AZEVEDO A, Perez RM, Moraes Coelho HS, Fernandes ES, et al
    The Anti-inflammatory Role of Propranolol in Cirrhosis: Preventing the Inflammatory Exhaustion?
    J Hepatol. 2016 Aug 16. pii: S0168-8278(16)30432.
    PubMed     Text format    


  95. HEDEGAARD DL, Tully DC, Rowe IA, Reynolds GM, et al
    High resolution sequencing of hepatitis C virus reveals limited intra-hepatic compartmentalization in end stage liver disease.
    J Hepatol. 2016 Aug 13. pii: S0168-8278(16)30424.
    PubMed     Text format     Abstract available


  96. MINAMI T, Tateishi R, Nakagomi R, Fujiwara N, et al
    The impact of direct-acting antivirals on early tumor recurrence after radiofrequency ablation in hepatitis C-related hepatocellular carcinoma.
    J Hepatol. 2016 Aug 11. pii: S0168-8278(16)30419.
    PubMed     Text format    


  97. KLOMPENHOUWER AJ, Sprengers D, Willemssen FE, Gaspersz MP, et al
    Evidence of good prognosis of hepatocellular adenoma in post-menopausal women.
    J Hepatol. 2016 Aug 11. pii: S0168-8278(16)30423.
    PubMed     Text format     Abstract available


  98. WEISS N, Hilaire PB, Colsch B, Isnard F, et al
    Cerebrospinal fluid metabolomics highlights dysregulation of energy metabolism in overt hepatic encephalopathy.
    J Hepatol. 2016 Aug 9. pii: S0168-8278(16)30422.
    PubMed     Text format     Abstract available


  99. LI G, Liu D, Cooper TK, Kimchi ET, et al
    Successful Chemoimmunotherapy against Hepatocellular Cancer in a Novel Murine Mode.
    J Hepatol. 2016 Aug 9. pii: S0168-8278(16)30420.
    PubMed     Text format     Abstract available


  100. LUUKKONEN PK, Zhou Y, Hyotylainen T, Leivonen M, et al
    The MBOAT7 variant rs641738 alters hepatic phosphatidylinositols and increases severity of non-alcoholic fatty liver disease in humans.
    J Hepatol. 2016 Aug 9. pii: S0168-8278(16)30421.
    PubMed     Text format    


    July 2016
  101. KOLLY P, Dufour JF
    Reply to <<Lack of evidence of an effect of Direct Acting Antivirals on the recurrence of hepatocellular carcinoma: The ANRS collaborative study group on hepatocellular carcinoma (ANRS CO22 HEPATHER, CO12 CIRVIR and CO23 CUPILT cohorts)>>.
    J Hepatol. 2016 Jul 29. pii: S0168-8278(16)30402.
    PubMed     Text format    


  102. CARDOSO H, Vale AM, Rodrigues S, Goncalves R, et al
    High incidence of hepatocellular carcinoma following successful interferon-free antiviral therapy for hepatitis C associated cirrhosis.
    J Hepatol. 2016 Jul 28. pii: S0168-8278(16)30397.
    PubMed     Text format    


  103. MITTAL S, Kanwal F, Ying J, Chung R, et al
    Effectiveness of Surveillance for Hepatocellular Carcinoma in Clinical Practice: A United States cohort.
    J Hepatol. 2016 Jul 28. pii: S0168-8278(16)30395.
    PubMed     Text format     Abstract available


  104. ZENG QL, Li ZQ, Liang HX, Xu GH, et al
    Unexpected high incidence of hepatocellular carcinoma in patients with hepatitis C in the era of DAAs: too alarming?
    J Hepatol. 2016 Jul 28. pii: S0168-8278(16)30399.
    PubMed     Text format    


  105. PALANIYAPPAN N, Cox E, Bradley C, Scott R, et al
    Non-invasive assessment of Portal Hypertension Using Quantitative Magnetic Resonance Imaging.
    J Hepatol. 2016 Jul 27. pii: S0168-8278(16)30348.
    PubMed     Text format     Abstract available


  106. WANG HL, Cucchetti A, Zhong JH, Ye XP, et al
    Should hepatic resection be recommended to patients with hepatocellular carcinoma and portal vein invasion?
    J Hepatol. 2016 Jul 27. pii: S0168-8278(16)30349.
    PubMed     Text format    


  107. MARUBASHI S, Sakon M
    "Local recurrence" is not equal to "Local dissemination" after resection for hepatocellular carcinoma.
    J Hepatol. 2016 Jul 21. pii: S0168-8278(16)30340.
    PubMed     Text format    


  108. SHINDOH J, Hasegawa K, Matsuyama Y, Makuuchi M, et al
    Reply to: "Local recurrence" is not equal to "Local dissemination" after resection for hepatocellular carcinoma.
    J Hepatol. 2016 Jul 20. pii: S0168-8278(16)30341.
    PubMed     Text format    


  109. BENECHET AP, Iannacone M
    Determinants of hepatic effector CD8+ T cell dynamics.
    J Hepatol. 2016 Jul 13. pii: S0168-8278(16)30335.
    PubMed     Text format     Abstract available


  110. SOLA E, Kerbert JC, Verspaget HW, Moreira R, et al
    Plasma copeptin as biomarker of disease progression and prognosis in cirrhosis.
    J Hepatol. 2016 Jul 12. pii: S0168-8278(16)30326.
    PubMed     Text format     Abstract available


  111. NAULT JC, Colombo M
    Hepatocellular carcinoma and direct acting antiviral treatments: Controversy after the revolution.
    J Hepatol. 2016 Jul 11. pii: S0168-8278(16)30327.
    PubMed     Text format    


  112. GEHRKE N, Worns MA, Huber Y, Hess M, et al
    Hepatic B cell leukemia-3 promotes hepatic steatosis and inflammation through insulin-sensitive metabolic transcription factors.
    J Hepatol. 2016 Jul 9. pii: S0168-8278(16)30322.
    PubMed     Text format     Abstract available


  113. ALAVI M, Law MG, Grebely J, Amin J, et al
    Time to decompensated cirrhosis and hepatocellular carcinoma after an HBV or HCV notification: a population-based study, 1995-2012.
    J Hepatol. 2016 Jul 8. pii: S0168-8278(16)30321.
    PubMed     Text format     Abstract available


  114. YANG JD, Aqel BA, Pungpapong S, Gores GJ, et al
    Direct Acting Antiviral Therapy and Tumor Recurrence after Liver Transplant for Hepatitis C-Associated Hepatocellular Carcinoma.
    J Hepatol. 2016 Jul 5. pii: S0168-8278(16)30318.
    PubMed     Text format    


  115. STEIN E, Cruz-Lemini M, Altamirano J, Ndugga N, et al
    Heavy daily alcohol intake at the population level predicts the weight of alcohol in cirrhosis burden worldwide.
    J Hepatol. 2016 Jul 5. pii: S0168-8278(16)30307.
    PubMed     Text format     Abstract available


  116. CHEUNG MC, Walker AJ, Hudson BE, Verma S, et al
    Outcomes after successful direct acting antiviral therapy for patients with chronic hepatitis C and decompensated cirrhosis.
    J Hepatol. 2016 Jul 4. pii: S0168-8278(16)30314.
    PubMed     Text format     Abstract available


  117. SCHUELLER F, Roy S, Trautwein C, Luedde T, et al
    miR-122 expression is not regulated during activation of hepatic stellate cells.
    J Hepatol. 2016 Jul 4. pii: S0168-8278(16)30308.
    PubMed     Text format    


  118. MAURICE J, Brodkin E, Arnold F, Navaratnam A, et al
    Validation of the Baveno Vi Criteria to Identify Low Risk Cirrhotic Patients not Requiring Endoscopic Surveillance for Varices.
    J Hepatol. 2016 Jul 4. pii: S0168-8278(16)30316.
    PubMed     Text format     Abstract available


  119. LI J, Li S
    Response to Letter to the Editor on comments on "miR-122 regulates collagen production via targeting hepatic stellate cells and suppressing P4HA1 expression. Li J, et al. J Hepatol 2013;58:522-528."
    J Hepatol. 2016 Jul 4. pii: S0168-8278(16)30315.
    PubMed     Text format    


    June 2016
  120. CHOI SH, Byun JH
    Reply to: "Conclusive HCC diagnosis with hepatocyte-specific contrast-enhanced magnetic resonance imaging? Not yet".
    J Hepatol. 2016 Jun 24. pii: S0168-8278(16)30306.
    PubMed     Text format    


  121. CONTI F, Buonfiglioli F, Scuteri A, Crespi C, et al
    Early Occurrence and Recurrence of Hepatocellular Carcinoma in HCV-related Cirrhosis Treated with Direct Acting Antivirals.
    J Hepatol. 2016 Jun 24. pii: S0168-8278(16)30303.
    PubMed     Text format     Abstract available


  122. PINATO DJ, Stebbing J, Ishizuka M, Khan SA, et al
    Corrigendum to "A novel and validated prognostic index in hepatocellular carcinoma: The Inflammation Based Index (IBI)".
    J Hepatol. 2016 Jun 16. pii: S0168-8278(16)30205.
    PubMed     Text format    


  123. VAN MEER S, Lieveld FI, van Erpecum KJ
    Patients' misconceptions about surveillance for hepatocellular carcinoma: Education is needed.
    J Hepatol. 2016 Jun 16. pii: S0168-8278(16)30274.
    PubMed     Text format    


  124. KOZBIAL K, Moser S, Schwarzer R, Laferl H, et al
    Unexpected high incidence of hepatocellular carcinoma in cirrhotic patients with SVR following IFN-free DAA treatment.
    J Hepatol. 2016 Jun 15. pii: S0168-8278(16)30271.
    PubMed     Text format    


  125. DAVULURI G, Krokowski D, Guan BJ, Kumar A, et al
    Metabolic adaptation of skeletal muscle to hyperammonemia drives the beneficial effects of L-leucine in cirrhosis.
    J Hepatol. 2016 Jun 15. pii: S0168-8278(16)30266.
    PubMed     Text format     Abstract available


  126. RATZIU V, Marchesini G
    When the journey from obesity to cirrhosis takes an early start.
    J Hepatol. 2016 Jun 14. pii: S0168-8278(16)30207.
    PubMed     Text format    


  127. DULAI PS, Sirlin CB, SLoomba R
    MRI and MRE for non-invasive quantitative assessment of hepatic steatosis and fibrosis in NAFLD and NASH: Clinical trials to clinical practice.
    J Hepatol. 2016 Jun 13. pii: S0168-8278(16)30267.
    PubMed     Text format     Abstract available


  128. SINCLAIR M, Grossmann M, Hoermann R, Angus PW, et al
    Testosterone therapy increases muscle mass in men with cirrhosis and low testosterone: A randomised controlled trial.
    J Hepatol. 2016 Jun 13. pii: S0168-8278(16)30269.
    PubMed     Text format     Abstract available


  129. FORNER A, Rimola J, Ayuso C
    Conclusive HCC diagnosis with hepatocyte-specific contrast-enhanced magnetic resonance imaging? Not yet.
    J Hepatol. 2016 Jun 13. pii: S0168-8278(16)30265.
    PubMed     Text format    


  130. KALAMBOKIS GN, Oikonomou A, Christou L, Kolaitis NI, et al
    von Willebrand factor and procoagulant imbalance independently predict outcome in patients with cirrhosis and thrombocytopenia.
    J Hepatol. 2016 Jun 10. pii: S0168-8278(16)30262.
    PubMed     Text format     Abstract available


  131. POL S
    Lack of evidence of an effect of Direct Acting Antivirals on the recurrence of hepatocellular carcinoma: The ANRS collaborative study group on hepatocellular carcinoma (ANRS CO22 HEPATHER, CO12 CIRVIR and CO23 CUPILT cohorts).
    J Hepatol. 2016 Jun 7. pii: S0168-8278(16)30259.
    PubMed     Text format     Abstract available


  132. KOKUDO T, Hasegawa K, Matsuyama Y, Takayama T, et al
    Survival benefit of liver resection for hepatocellular carcinoma associated with portal vein invasion.
    J Hepatol. 2016 Jun 4. pii: S0168-8278(16)30258.
    PubMed     Text format     Abstract available


  133. YE D, Yang K, Zang S, Lin Z, et al
    Lipocalin-2 Mediates Nonalcoholic Steatohepatitis by Promoting Neutrophil-Macrophage Crosstalk via The Induction of CXCR2.
    J Hepatol. 2016 Jun 4. pii: S0168-8278(16)30255.
    PubMed     Text format     Abstract available


  134. DHANASEKARAN R, Venkatesh SK, Torbenson MS, Roberts LR, et al
    Erratum to "Clinical implications of basic research in hepatocellular carcinoma" [J Hepatol 2016;64:736-745].
    J Hepatol. 2016;64:1462.
    PubMed     Text format    


  135. YEUNG OW, Lo CM, Ling CC, Qi X, et al
    Corrigendum to "Alternatively activated (M2) macrophages promote tumour growth and invasiveness in hepatocellular carcinoma" [J Hepatol 2015;62:607-616].
    J Hepatol. 2016;64:1461.
    PubMed     Text format    


  136. FUNG J, Seto WK, Lai CL, Yuen J, et al
    Corrigendum to "Profiles of HBV DNA in a large population of Chinese patients with chronic hepatitis B: Implications for antiviral therapy" [J Hepatol 2011;54:195-200].
    J Hepatol. 2016;64:1460.
    PubMed     Text format    


  137. SCHULZE K, Nault JC, Villanueva A
    Genetic profiling of hepatocellular carcinoma using next-generation sequencing.
    J Hepatol. 2016 Jun 1. pii: S0168-8278(16)30249.
    PubMed     Text format     Abstract available


    May 2016
  138. TORRES HA, Vauthey JN, Economides MP, Mahale P, et al
    Hepatocellular carcinoma recurrence after treatment with direct-acting antivirals: First, do no harm by withdrawing treatment.
    J Hepatol. 2016 May 30. pii: S0168-8278(16)30248.
    PubMed     Text format    


  139. BOZIC M, Guzman C, Benet M, Sanchez-Campos S, et al
    VDR expression is up-regulated in NAFLD hepatocytes and is required for high fat diet-induced steatosis in apoE mice liver.
    J Hepatol. 2016 May 28. pii: S0168-8278(16)30243.
    PubMed     Text format     Abstract available


  140. MANDORFER M, Kozbial K, Schwabl P, Freissmuth C, et al
    Sustained virologic response to interferon-free therapies ameliorates HCV-induced portal hypertension.
    J Hepatol. 2016 May 27. pii: S0168-8278(16)30238.
    PubMed     Text format     Abstract available


  141. NADIM MK, Durand F, Kellum JA, Levitsky J, et al
    Corrigendum to "Management of the critically ill patients with cirrhosis: A multidisciplinary perspective".
    J Hepatol. 2016 May 27. pii: S0168-8278(16)30185.
    PubMed     Text format    


  142. MANI SK, Zhang H, Diab A, Pascuzzi PE, et al
    EpCAM-Regulated Intramembrane Proteolysis Induces a Cancer Stem Cell-like Gene Signature in Hepatitis B Virus-infected Hepatocytes.
    J Hepatol. 2016 May 26. pii: S0168-8278(16)30208.
    PubMed     Text format     Abstract available


  143. FRANCOZ C, Nadim MK, Durand F
    Kidney Biomarkers in Cirrhosis.
    J Hepatol. 2016 May 26. pii: S0168-8278(16)30211.
    PubMed     Text format     Abstract available


  144. BOYD A, Lacombe K, Lavocat F, Maylin S, et al
    Decay of ccc-DNA is slow and marks persistence of intrahepatic viral DNA synthesis under tenofovir in HIV-HBV co-infected patients.
    J Hepatol. 2016 May 19. pii: S0168-8278(16)30200.
    PubMed     Text format     Abstract available


  145. TSENG A, Wong DK
    Hepatotoxicity and Potential Drug Interaction with Ledipasvir/Sofosbuvir In HIV/HCV Infected Patients.
    J Hepatol. 2016 May 19. pii: S0168-8278(16)30201.
    PubMed     Text format     Abstract available


  146. SHEN J, Jiang F, Yang Y, Huang G, et al
    14-3-3eta, a novel growth-promoting factor in hepatocellular carcinoma, not only in tumor but also in intratumoral vessels.
    J Hepatol. 2016 May 19. pii: S0168-8278(16)30203.
    PubMed     Text format     Abstract available


  147. GIANNELLI G, Koudelkova P, Dituri F, Mikulits W, et al
    Role of epithelial to mesenchymal transition in hepatocellular carcinoma.
    J Hepatol. 2016 May 17. pii: S0168-8278(16)30193.
    PubMed     Text format     Abstract available


  148. OLESEN SS, Gram M, Jackson CD, Halliday E, et al
    Electroencephalogram variability in patients with cirrhosis associates with the presence and severity of hepatic encephalopathy.
    J Hepatol. 2016 May 13. pii: S0168-8278(16)30189.
    PubMed     Text format     Abstract available


  149. ASGHARPOUR A, Cazanave SC, Pacana T, Seneshaw M, et al
    A preclinical mouse model of nonalcoholic steatohepatitis and hepatocellular cancer that mimics human disease.
    J Hepatol. 2016 May 13. pii: S0168-8278(16)30190.
    PubMed     Text format     Abstract available


  150. VANDENBULCKE H, Moreno C, Colle I, Knebel JF, et al
    Alcohol intake increases the risk of hepatocellular carcinoma in patients with hepatitis C virus-related compensated cirrhosis: a prospective study.
    J Hepatol. 2016 May 12. pii: S0168-8278(16)30184.
    PubMed     Text format     Abstract available


  151. JIAO J, Ooka K, Fey H, Fiel MI, et al
    Interleukin-15 Receptor alpha on Hepatic Stellate Cells Controls Fibrogenesis In Murine Liver Injury.
    J Hepatol. 2016 May 3. pii: S0168-8278(16)30164.
    PubMed     Text format     Abstract available


  152. BILLERBECK E, Mommersteeg MC, Shlomai A, Xiao JW, et al
    Humanized mice efficiently engrafted with fetal hepatoblasts and syngeneic immune cells develop human monocytes and NK cells.
    J Hepatol. 2016 May 2. pii: S0168-8278(16)30166.
    PubMed     Text format     Abstract available


  153. TOUBAL A, Lehuen A
    Lights on MAIT cells, a new immune player in liver diseases.
    J Hepatol. 2016;64:1008-10.
    PubMed     Text format    


  154. GALLE PR
    EASL Recognition Award Recipient 2016: Prof. Jordi Bruix.
    J Hepatol. 2016;64:998-1000.
    PubMed     Text format    


  155. BOSCH J
    EASL International Recognition Award Recipient 2016: Prof. Roberto J. Groszmann.
    J Hepatol. 2016;64:996-7.
    PubMed     Text format    


  156. IJSSENNAGGER N, Janssen AW, Milona A, Ramos Pittol JM, et al
    Gene expression profiling in human precision cut liver slices in response to the FXR agonist obeticholic acid.
    J Hepatol. 2016;64:1158-66.
    PubMed     Text format     Abstract available


  157. NOLL J, Helk E, Fehling H, Bernin H, et al
    IL-23 prevents IL-13-dependent tissue repair associated with Ly6C(lo) monocytes in Entamoeba histolytica-induced liver damage.
    J Hepatol. 2016;64:1147-57.
    PubMed     Text format     Abstract available


  158. LENCIONI R, Llovet JM, Han G, Tak WY, et al
    Sorafenib or placebo plus TACE with doxorubicin-eluting beads for intermediate stage HCC: The SPACE trial.
    J Hepatol. 2016;64:1090-8.
    PubMed     Text format     Abstract available


  159. LUUKKONEN PK, Zhou Y, Sadevirta S, Leivonen M, et al
    Hepatic ceramides dissociate steatosis and insulin resistance in patients with non-alcoholic fatty liver disease.
    J Hepatol. 2016;64:1167-75.
    PubMed     Text format     Abstract available


  160. QU C, He D, Lu X, Dong L, et al
    Salt-inducible Kinase (SIK1) regulates HCC progression and WNT/beta-catenin activation.
    J Hepatol. 2016;64:1076-89.
    PubMed     Text format     Abstract available


  161. SORG UR, Behnke K, Degrandi D, Reich M, et al
    Cooperative role of lymphotoxin beta receptor and tumor necrosis factor receptor p55 in murine liver regeneration.
    J Hepatol. 2016;64:1108-17.
    PubMed     Text format     Abstract available


  162. TRIVEDI PJ, Adams DH
    Gut-liver immunity.
    J Hepatol. 2016;64:1187-9.
    PubMed     Text format     Abstract available


    April 2016
  163. OGLE LF, Orr JG, Willoughby CE, Hutton C, et al
    Imagestream detection and characterisation of circulating tumour cells - a liquid biopsy for Hepatocellular Carcinoma?
    J Hepatol. 2016 Apr 27. pii: S0168-8278(16)30146.
    PubMed     Text format     Abstract available


  164. FOSTER G
    Reply to: "High mortality during direct acting antiviral therapy for hepatitis C patients with Child's C cirrhosis: Results of the Irish Early Access Programme".
    J Hepatol. 2016 Apr 27. pii: S0168-8278(16)30142.
    PubMed     Text format    


  165. GRAY E, O'Leary A, Stewart S, Bergin C, et al
    High mortality during direct acting antiviral therapy for hepatitis C patients with Child's C cirrhosis: Results of the Irish Early Access Programme.
    J Hepatol. 2016 Apr 27. pii: S0168-8278(16)30143.
    PubMed     Text format    


  166. ZHU AX, Chen D, He W, Kanai M, et al
    Integrative Biomarker Analyses Indicate Etiological Variations in Hepatocellular Carcinoma.
    J Hepatol. 2016 Apr 26. pii: S0168-8278(16)30147.
    PubMed     Text format     Abstract available


  167. ABOU-ALFA GK, Puig O, Daniele B, Kudo M, et al
    Randomized Phase II placebo controlled study of codrituzumab in previously treated patients with advanced hepatocellular carcinoma.
    J Hepatol. 2016 Apr 13. pii: S0168-8278(16)30106.
    PubMed     Text format     Abstract available


  168. REIG M, Marino Z, Perello C, Inarrairaegui M, et al
    Unexpected early tumor recurrence in patients with hepatitis C virus -related hepatocellular carcinoma undergoing interferon-free therapy: a note of caution.
    J Hepatol. 2016 Apr 12. pii: S0168-8278(16)30113.
    PubMed     Text format     Abstract available


  169. LULI S, Di Paolo D, Perri P, Brignole C, et al
    A new fluorescence based optical imaging method to non-invasively monitor hepatic myofibroblasts in vivo.
    J Hepatol. 2016 Apr 8. pii: S0168-8278(16)30104.
    PubMed     Text format     Abstract available


  170. YANG T, Shen F, Schwartz M
    Reply to: Association of blood transfusion during resection for hepatocellular carcinoma with postoperative recurrence and overall survival: a cautionary comment.
    J Hepatol. 2016 Apr 7. pii: S0168-8278(16)30102.
    PubMed     Text format    


  171. MO HY, Zhong JH, Qin HG
    Association of blood transfusion during resection for hepatocellular carcinoma with postoperative recurrence and overall survival: a cautionary comment.
    J Hepatol. 2016 Apr 4. pii: S0168-8278(16)30095.
    PubMed     Text format    


  172. VERSLYPE C
    Interfering with epigenetics in hepatocellular carcinoma: out of the shelter?
    J Hepatol. 2016 Apr 4. pii: S0168-8278(16)30098.
    PubMed     Text format    


  173. LEVRERO M, Zucman-Rossi J
    Mechanisms of HBV-induced hepatocellular carcinoma.
    J Hepatol. 2016;64.
    PubMed     Text format     Abstract available


  174. LI W, Urban S
    Entry of hepatitis B and hepatitis D virus into hepatocytes: Basic insights and clinical implications.
    J Hepatol. 2016;64.
    PubMed     Text format     Abstract available



  175. Corrigendum to ''Allo-transplantation of mesenchymal stem cells attenuates hepatic injury through IL1Ra dependent macrophage switch in a mouse model of liver disease" [J Hepatol 2015;63:1405-1412].
    J Hepatol. 2016;64:989.
    PubMed     Text format    


  176. MUSSO G, Cassader M, Paschetta E, Gambino R, et al
    TM6SF2 may drive postprandial lipoprotein cholesterol toxicity away from the vessel walls to the liver in NAFLD.
    J Hepatol. 2016;64:979-81.
    PubMed     Text format    


  177. MARI M, Tutusaus A, Garcia de Frutos P, Morales A, et al
    Genetic and clinical data reinforce the role of GAS6 and TAM receptors in liver fibrosis.
    J Hepatol. 2016;64:983-4.
    PubMed     Text format    


  178. PETTA S, Marra F
    Reply to 'Genetic and clinical data reinforce the role of GAS6 and TAM receptors in liver fibrosis'.
    J Hepatol. 2016;64:984-5.
    PubMed     Text format    


  179. PIROLA CJ, Sookoian S
    The modulation of liver methylome in liver diseases.
    J Hepatol. 2016;64:987-8.
    PubMed     Text format    


  180. WIESER V, Tymoszuk P, Adolph TE, Grander C, et al
    Lipocalin 2 drives neutrophilic inflammation in alcoholic liver disease.
    J Hepatol. 2016;64:872-80.
    PubMed     Text format     Abstract available


  181. YIN H, Bogorad RL, Barnes C, Walsh S, et al
    RNAi-nanoparticulate manipulation of gene expression as a new functional genomics tool in the liver.
    J Hepatol. 2016;64:899-907.
    PubMed     Text format     Abstract available


  182. WESTBROOK RH, Dusheiko G, Williamson C
    Pregnancy and liver disease.
    J Hepatol. 2016;64:933-45.
    PubMed     Text format     Abstract available


  183. JURIC V, Ruffell B, Evason KJ, Hu J, et al
    Monocytes promote liver carcinogenesis in an oncogene-specific manner.
    J Hepatol. 2016;64:881-90.
    PubMed     Text format     Abstract available


  184. GHALLAB A, Celliere G, Henkel SG, Driesch D, et al
    Model-guided identification of a therapeutic strategy to reduce hyperammonemia in liver diseases.
    J Hepatol. 2016;64:860-71.
    PubMed     Text format     Abstract available


  185. JUNKER AE, Gluud LL, van Hall G, Holst JJ, et al
    Effects of glucagon-like peptide-1 on glucagon secretion in patients with non-alcoholic fatty liver disease.
    J Hepatol. 2016;64:908-15.
    PubMed     Text format     Abstract available


  186. SHERON N
    Alcohol and liver disease in Europe--Simple measures have the potential to prevent tens of thousands of premature deaths.
    J Hepatol. 2016;64:957-67.
    PubMed     Text format     Abstract available


    March 2016
  187. TADA T, Kumada T, Toyoda H, Kiriyama S, et al
    HBcrAg is a predictor of hepatocellular carcinoma development: an analysis using time-dependent receiver operating characteristics.
    J Hepatol. 2016 Mar 28. pii: S0168-8278(16)30086.
    PubMed     Text format     Abstract available


  188. ZHONG JH, Mo HY, Li LQ
    Hepatic venous pressure gradient for preoperative assessment of patients with resectable hepatocellular carcinoma: a comment for moving forward.
    J Hepatol. 2016 Mar 28. pii: S0168-8278(16)30082.
    PubMed     Text format    


  189. CUCCHETTI A, Cescon M, Pinna AD
    Reply to "Hepatic venous pressure gradient for preoperative assessment of patients with resectable hepatocellular carcinoma: a comment for moving forward".
    J Hepatol. 2016 Mar 26. pii: S0168-8278(16)30087.
    PubMed     Text format    


  190. GAO L, Wang PX, Zhang Y, Yu CJ, et al
    Tumor necrosis factor receptor-associated factor 5 (Traf5) acts as an essential negative regulator of hepatic steatosis.
    J Hepatol. 2016 Mar 23. pii: S0168-8278(16)30077.
    PubMed     Text format     Abstract available


  191. BRUNO S, Di Marco V, Iavarone M, Roffi L, et al
    Survival of patients with HCV cirrhosis and sustained virologic response is similar to the general population.
    J Hepatol. 2016 Mar 23. pii: S0168-8278(16)00075.
    PubMed     Text format     Abstract available


  192. XIE L, Wang PX, Zhang P, Zhang XJ, et al
    DKK3 expression in hepatocytes defines susceptibility to liver steatosis and obesity.
    J Hepatol. 2016 Mar 22. pii: S0168-8278(16)30079.
    PubMed     Text format     Abstract available


  193. ARIZA X, Graupera I, Coll M, Sola E, et al
    Neutrophil gelatinase-associated lipocalin is a biomarker of acute-on-chronic liver failure and prognosis in cirrhosis.
    J Hepatol. 2016 Mar 14. pii: S0168-8278(16)30029.
    PubMed     Text format     Abstract available


  194. LIU X, Burhans MS, Flowers MT, Ntambi JM, et al
    Hepatic oleate regulates liver stress response partially through PGC-1alpha during high-carbohydrate feeding.
    J Hepatol. 2016 Mar 11. pii: S0168-8278(16)30028.
    PubMed     Text format     Abstract available


  195. BITZER M, Horger M, Giannini EG, Ganten TM, et al
    Resminostat in combination with sorafenib as second-line therapy of advanced hepatocellular carcinoma - The SHELTER Study.
    J Hepatol. 2016 Mar 4. pii: S0168-8278(16)30009.
    PubMed     Text format     Abstract available


  196. CURRY MP
    DAA for decompensated cirrhosis. Efficacy and safety are now established.
    J Hepatol. 2016 Mar 3. pii: S0168-8278(16)30007.
    PubMed     Text format    


  197. KIM YH, Hwang JH, Noh JR, Lee CH, et al
    Reply to "Repurposing of metformin in liver injury: The JNK conundrum".
    J Hepatol. 2016;64:750-2.
    PubMed     Text format    


  198. RAMAKRISHNA G, Sen B, Trehanpati N, Sarin SK, et al
    Repurposing of metformin in liver injury: The JNK conundrum.
    J Hepatol. 2016;64:749-50.
    PubMed     Text format    


  199. PETTA S, Valenti L, Marra F, Grimaudo S, et al
    MERTK rs4374383 polymorphism affects the severity of fibrosis in non-alcoholic fatty liver disease.
    J Hepatol. 2016;64:682-90.
    PubMed     Text format     Abstract available


  200. MOOKERJEE RP, Pavesi M, Thomsen KL, Mehta G, et al
    Treatment with non-selective beta blockers is associated with reduced severity of systemic inflammation and improved survival of patients with acute-on-chronic liver failure.
    J Hepatol. 2016;64:574-82.
    PubMed     Text format     Abstract available


    February 2016
  201. TOUBOUL T, Chen S, To CC, Mora-Castilla S, et al
    Stage-specific regulation of the WNT/beta-catenin pathway results in improved differentiation of hESCs to functional hepatocytes.
    J Hepatol. 2016 Feb 24. pii: S0168-8278(16)00162.
    PubMed     Text format     Abstract available


  202. HANNOUN Z, Steichen C, Dianat N, Weber A, et al
    The Potential of Induced Pluripotent Stem Cell derived Hepatocytes.
    J Hepatol. 2016 Feb 22. pii: S0168-8278(16)00158.
    PubMed     Text format     Abstract available


  203. BUCSICS T, Schwabl P, Mandorfer M, Peck-Radosavljevic M, et al
    Prognosis of cirrhotic patients with fungiascites and spontaneous fungal peritonitis (SFP).
    J Hepatol. 2016 Feb 22. pii: S0168-8278(16)00155.
    PubMed     Text format    


  204. ALEXOPOULOU A, Vasilieva L, Agiasotelli D, Dourakis SP, et al
    Reply to "Prognosis of cirrhotic patients with fungiascites and spontaneous fungal peritonitis".
    J Hepatol. 2016 Feb 20. pii: S0168-8278(16)00121.
    PubMed     Text format    


  205. ADHOUTE X, Penaranda G, Raoul JL, Bourliere M, et al
    Hepatocellular carcinoma scoring and staging systems. Do we need new tools?
    J Hepatol. 2016 Feb 18. pii: S0168-8278(16)00150.
    PubMed     Text format    


  206. LIU PH, Huo TI
    Prognosis of Hepatocellular Carcinoma: Can Scores Guide Treatment Decisions?
    J Hepatol. 2016 Feb 18. pii: S0168-8278(16)00149.
    PubMed     Text format    


  207. LOUVET A
    Restoration of bactericidal activity of neutrophils by myeloperoxidase release: a new perspective for preventing infection in alcoholic cirrhosis.
    J Hepatol. 2016 Feb 13. pii: S0168-8278(16)00125.
    PubMed     Text format    


  208. VAN DER WOERD WL, Wichers CG, Vestergaard AL, Andersen JP, et al
    Defective plasma membrane targeting of p.I661T-ATP8B1, associated with familial intrahepatic cholestasis, can be rescued in vitro by CFTR correctors.
    J Hepatol. 2016 Feb 12. pii: S0168-8278(16)00076.
    PubMed     Text format     Abstract available


  209. CHIU YT, Wong JK, Choi SW, Sze KM, et al
    Novel pre-mRNA splicing of intronically integrated HBV generates oncogenic chimera in hepatocellular carcinoma.
    J Hepatol. 2016 Feb 8. pii: S0168-8278(16)00084.
    PubMed     Text format     Abstract available


  210. BALA S, Csak T, Saha B, Zatsiorsky J, et al
    The pro-inflammatory effects of miR-155 promote liver fibrosis and alcohol-induced steatohepatitis.
    J Hepatol. 2016 Feb 8. pii: S0168-8278(16)00078.
    PubMed     Text format     Abstract available


  211. XIANG M, Wang PX, Wang AB, Zhang XJ, et al
    Targeting hepatic TRAF1-ASK1 signaling to improve inflammation, insulin resistance, and hepatic steatosis.
    J Hepatol. 2016 Feb 6. pii: S0168-8278(16)00077.
    PubMed     Text format     Abstract available


  212. YOVCHEV MI, Locker J, Oertel M
    Biliary fibrosis drives liver repopulation and phenotype transition of transplanted hepatocytes.
    J Hepatol. 2016 Feb 5. pii: S0168-8278(16)00079.
    PubMed     Text format     Abstract available


  213. PIETRANGELO A
    Mechanisms of iron hepatotoxicity.
    J Hepatol. 2016 Feb 5. pii: S0168-8278(16)00080.
    PubMed     Text format    


  214. LEE YH, Cha BS
    Reply to "The association between sarcopenia and non-alcoholic fatty liver disease: Potential pitfalls in non-invasive prediction models".
    J Hepatol. 2016;64:520-1.
    PubMed     Text format    


  215. KIM CW, Kim HY
    The association between sarcopenia and non-alcoholic fatty liver disease: Potential pitfalls in non-invasive prediction models.
    J Hepatol. 2016;64:519-20.
    PubMed     Text format    


  216. GASTALDELLI A, Marchesini G
    Time for Glucagon like peptide-1 receptor agonists treatment for patients with NAFLD?
    J Hepatol. 2016;64:262-4.
    PubMed     Text format    


  217. ROY-CHOWDHURY J, Schilsky ML
    Gene therapy of Wilson disease: A "golden" opportunity using rAAV on the 50th anniversary of the discovery of the virus.
    J Hepatol. 2016;64:265-7.
    PubMed     Text format    


  218. LUNA JM, Michailidis E, Rice CM
    Mopping up miRNA: An integrated HBV transcript disrupts liver homeostasis by sequestering miR-122.
    J Hepatol. 2016;64:257-9.
    PubMed     Text format    


  219. MURILLO O, Luqui DM, Gazquez C, Martinez-Espartosa D, et al
    Long-term metabolic correction of Wilson's disease in a murine model by gene therapy.
    J Hepatol. 2016;64:419-26.
    PubMed     Text format     Abstract available


  220. ZUBIETE-FRANCO I, Garcia-Rodriguez JL, Martinez-Una M, Martinez-Lopez N, et al
    Methionine and S-adenosylmethionine levels are critical regulators of PP2A activity modulating lipophagy during steatosis.
    J Hepatol. 2016;64:409-18.
    PubMed     Text format     Abstract available


  221. ARMSTRONG MJ, Hull D, Guo K, Barton D, et al
    Glucagon-like peptide 1 decreases lipotoxicity in non-alcoholic steatohepatitis.
    J Hepatol. 2016;64:399-408.
    PubMed     Text format     Abstract available


    January 2016
  222. FOSTER GR, Irving WL, Cheung MC, Walker AJ, et al
    Cohort study of the impact of direct acting antiviral therapy in patients with chronic hepatitis C and decompensated cirrhosis.
    J Hepatol. 2016 Jan 29. pii: S0168-8278(16)00065.
    PubMed     Text format     Abstract available


  223. TREBICKA J, von Heydebrand M, Lehmann J, Tofteng F, et al
    Assessment of beta-blocker response by expression of beta-Arrestin2 and RhoA/ROCK2 in antrum mucosa in cirrhotic patients.
    J Hepatol. 2016 Jan 28. pii: S0168-8278(16)00057.
    PubMed     Text format     Abstract available


  224. CHOI SH, Byun JH, Lim YS, Yu E, et al
    Diagnostic criteria for hepatocellular carcinoma 3 cm with hepatocyte-specific contrast-enhanced magnetic resonance imaging.
    J Hepatol. 2016 Jan 25. pii: S0168-8278(16)00052.
    PubMed     Text format     Abstract available


  225. WILD SH, Morling JR, McAllister DA, Kerssens J, et al
    Type 2 diabetes, chronic liver disease and hepatocellular cancer: a national retrospective cohort study using linked routine data.
    J Hepatol. 2016 Jan 23. pii: S0168-8278(16)00020.
    PubMed     Text format     Abstract available


  226. NOIRET L, Rose CF
    Mathematical models and hepatology; oil and vinegar?
    J Hepatol. 2016 Jan 23. pii: S0168-8278(16)00055.
    PubMed     Text format    


  227. UDOMPAP P, Mannalithara A, Heo N, Kim D, et al
    Increasing Prevalence of Cirrhosis among US Adults Aware or Unaware of their Chronic Hepatitis C Virus Infection.
    J Hepatol. 2016 Jan 22. pii: S0168-8278(16)00014.
    PubMed     Text format     Abstract available


  228. BOSCH J, Sauerbruch T
    Esophageal varices: Stage-dependent treatment algorithm.
    J Hepatol. 2016 Jan 19. pii: S0168-8278(15)00801.
    PubMed     Text format    


  229. LUA I, Li Y, Zagory JA, Wang KS, et al
    Characterization of hepatic stellate cells, portal fibroblasts, and mesothelial cells in normal and fibrotic livers.
    J Hepatol. 2016 Jan 19. pii: S0168-8278(16)00015.
    PubMed     Text format     Abstract available


  230. YANG YH, Chen WC, Tsai YH, Chen PC, et al
    Reply to "Statin use and the risk of cirrhosis development in patients with hepatitis C virus infection".
    J Hepatol. 2016 Jan 18. pii: S0168-8278(16)00011.
    PubMed     Text format    


  231. MCPHAIL MJ, Shawcross DL, Lewis MR, Coltart I, et al
    Multivariate metabotyping of plasma accurately predicts survival in patients with decompensated cirrhosis.
    J Hepatol. 2016 Jan 18. pii: S0168-8278(16)00006.
    PubMed     Text format     Abstract available


  232. FIORE M, Leone S
    Use of anti-fungals in critically ill cirrhotic patients with spontaneous peritonitis.
    J Hepatol. 2016 Jan 18. pii: S0168-8278(16)00013.
    PubMed     Text format    


  233. HOOFNAGLE JH
    Hepatic Decompensation during Direct-Acting Antiviral Therapy of Chronic Hepatitis C.
    J Hepatol. 2016 Jan 18. pii: S0168-8278(16)00010.
    PubMed     Text format    


  234. YU ML
    Statin use and the risk of cirrhosis development in patients with hepatitis C virus infection.
    J Hepatol. 2016 Jan 18. pii: S0168-8278(16)00012.
    PubMed     Text format    


  235. NAGAMOTO Y, Takayama K, Ohashi K, Okamoto R, et al
    Enhancement of survival rate by human iPSC-derived hepatocyte sheet transplantation in acute liver failure mice.
    J Hepatol. 2016 Jan 14. pii: S0168-8278(16)00007.
    PubMed     Text format     Abstract available


  236. JALAN R
    Journal of Hepatology, 2016.
    J Hepatol. 2016;64:5-7.
    PubMed     Text format    


  237. PAROLA M
    Age-dependent changes in extracellular matrix turnover: An under evaluated issue in the approach to chronic liver diseases.
    J Hepatol. 2016;64:13-5.
    PubMed     Text format    


  238. KARVELLAS CJ, Stravitz RT
    High volume plasma exchange in acute liver failure: Dampening the inflammatory cascade?
    J Hepatol. 2016;64:10-2.
    PubMed     Text format    


  239. CASTERA L
    Non-invasive tests for liver fibrosis progression and regression.
    J Hepatol. 2016;64:232-3.
    PubMed     Text format    



  240. EASL Clinical Practice Guidelines: Vascular diseases of the liver.
    J Hepatol. 2016;64:179-202.
    PubMed     Text format    


  241. ILYAS G, Zhao E, Liu K, Lin Y, et al
    Macrophage autophagy limits acute toxic liver injury in mice through down regulation of interleukin-1beta.
    J Hepatol. 2016;64:118-27.
    PubMed     Text format     Abstract available


  242. LARSEN FS, Schmidt LE, Bernsmeier C, Rasmussen A, et al
    High-volume plasma exchange in patients with acute liver failure: An open randomised controlled trial.
    J Hepatol. 2016;64:69-78.
    PubMed     Text format     Abstract available


  243. DYSON JK, Hutchinson J, Harrison L, Rotimi O, et al
    Liver toxicity associated with sofosbuvir, an NS5A inhibitor and ribavirin use.
    J Hepatol. 2016;64:234-8.
    PubMed     Text format     Abstract available


  244. KARSDAL MA, Genovese F, Madsen EA, Manon-Jensen T, et al
    Collagen and tissue turnover as a function of age: Implications for fibrosis.
    J Hepatol. 2016;64:103-9.
    PubMed     Text format     Abstract available


  245. JIANG M, Klein M, Zanger UM, Mohammad MK, et al
    Inflammatory regulation of steroid sulfatase: A novel mechanism to control estrogen homeostasis and inflammation in chronic liver disease.
    J Hepatol. 2016;64:44-52.
    PubMed     Text format     Abstract available


    December 2015
  246. JEFFERY HC, van Wilgenburg B, Kurioka A, Parekh K, et al
    Bacteria Exposed Biliary Epithelium and Liver B Cells Activate Intrahepatic Mait Cells in an MR1-Dependent Manner.
    J Hepatol. 2015 Dec 29. pii: S0168-8278(15)00858.
    PubMed     Text format     Abstract available


  247. OKAFOR PN, Chiejina M, de Pretis N, Talwalkar JA, et al
    Secondary Analysis of Large Databases for Hepatology Research.
    J Hepatol. 2015 Dec 28. pii: S0168-8278(15)00860.
    PubMed     Text format     Abstract available


  248. GARCIA-TSAO G
    Beta-Blockers in Cirrhosis: The Window Re-Opens.
    J Hepatol. 2015 Dec 24. pii: S0168-8278(15)00814.
    PubMed     Text format    


  249. WU L, Bartlett A, Plank L, McCall J, et al
    Validation of the Hong Kong Liver Cancer Staging System in Hepatocellular Carcinoma Patients Treated with Curative Intent.
    J Hepatol. 2015 Dec 23. pii: S0168-8278(15)00810.
    PubMed     Text format    


  250. UBEDA M, Lario M, Munoz L, Borrero MJ, et al
    Obeticholic acid reduces bacterial translocation, restores intestinal barrier and inhibits inflammation in cirrhotic rats.
    J Hepatol. 2015 Dec 23. pii: S0168-8278(15)00812.
    PubMed     Text format     Abstract available


  251. VAN MEER S, de Man RA, van Erpecum KJ
    How to implement available data on hepatocellular carcinoma surveillance in clinical practice?
    J Hepatol. 2015 Dec 22. pii: S0168-8278(15)00811.
    PubMed     Text format    


  252. FARRELL C, Cross TJ
    Re: van Meer S, de Man RA, Coenrad MJ, Sprengers D, van Nieuwkerk KMJ, Klupmpen HJ, et al. Surveillance for hepatocellular carcinoma is associated with increased survival: results from a large cohort study in the Netherlands. J Hepatol 2015; 63: 1156-
    J Hepatol. 2015 Dec 21. pii: S0168-8278(15)00809.
    PubMed     Text format    


  253. BOUSSIF A, Rolas L, Weiss E, Bouriche H, et al
    Impaired AKT/MAP-Kinase signaling, myeloperoxidase release and bactericidal activity of neutrophils from patients with alcoholic cirrhosis.
    J Hepatol. 2015 Dec 21. pii: S0168-8278(15)00806.
    PubMed     Text format     Abstract available


  254. CERINI F, Vilaseca M, Lafoz E, Garcia-Irigoyen O, et al
    Enoxaparin reduces hepatic vascular resistance and portal pressure in cirrhotic rats.
    J Hepatol. 2015 Dec 11. pii: S0168-8278(15)00804.
    PubMed     Text format     Abstract available


  255. SHERMAN M
    Staging for Hepatocellular Carcinoma: An Embarrassment of Riches.
    J Hepatol. 2015 Dec 9. pii: S0168-8278(15)00803.
    PubMed     Text format    


  256. PAPATHEODORIDIS G, Dalekos G, Sypsa V, Yurdaydin C, et al
    Page-B: Risk Score for Hepatocellular Carcinoma in Caucasians with Chronic Hepatitis B Under 5-Year Entecavir or Tenofovir Therapy.
    J Hepatol. 2015 Dec 8. pii: S0168-8278(15)00795.
    PubMed     Text format     Abstract available


  257. JALAN R, De Chiara F, Balasubramaniyan V, Andreola F, et al
    Ammonia produces pathological changes in human hepatic stellate cells and is a target of therapy of portal hypertension.
    J Hepatol. 2015 Dec 1. pii: S0168-8278(15)00777.
    PubMed     Text format     Abstract available


    November 2015
  258. KOOT BG, Alders M, Verheij J, Beuers UH, et al
    A de novo mutation in KCNN3 associated with autosomal dominant idiopathic non-cirrhotic portal hypertension.
    J Hepatol. 2015 Nov 30. pii: S0168-8278(15)00785.
    PubMed     Text format     Abstract available


  259. WELKER MW, Luhne S, Lange CM, Vermehren J, et al
    Lactic acidosis in patients with hepatitis C virus related cirrhosis and combined ribavirin/sofosbuvir treatment.
    J Hepatol. 2015 Nov 30. pii: S0168-8278(15)00792.
    PubMed     Text format     Abstract available


  260. MATTU S, Fornari F, Quagliata L, Perra A, et al
    The metabolic gene HAO2 is down regulated in mouse, rat and human hepatocellular carcinoma and correlates with metastasis and poor survival.
    J Hepatol. 2015 Nov 30. pii: S0168-8278(15)00787.
    PubMed     Text format     Abstract available


  261. HONG G, Suh KS, Suh S, Yoo T, et al
    Preoperative Alpha-fetoprotein and F-FDG PET Predict Tumor Recurrence better than Milan Criteria in Living Donor Liver Transplantation.
    J Hepatol. 2015 Nov 30. pii: S0168-8278(15)00791.
    PubMed     Text format     Abstract available


  262. GRONBAEK H, Rodgaard-Hansen S, Aagaard NK, Arroyo V, et al
    The soluble macrophage activation markers sCD163 and Mannose Receptor (sMR) predict mortality in patients with liver cirrhosis without or with acute-on-chronic liver failure (ACLF).
    J Hepatol. 2015 Nov 27. pii: S0168-8278(15)00779.
    PubMed     Text format     Abstract available


  263. WAN X, Xu C, Lin Y, Lu C, et al
    Uric acid regulates hepatic steatosis and insulin resistance through the NLRP3 inflammasome-dependent mechanism.
    J Hepatol. 2015 Nov 27. pii: S0168-8278(15)00780.
    PubMed     Text format     Abstract available


  264. VILGRAIN V, Van Beers BE, Pastor CM
    Insights into the diagnosis of hepatocellular carcinomas with hepatobiliary MRI.
    J Hepatol. 2015 Nov 26. pii: S0168-8278(15)00774.
    PubMed     Text format     Abstract available


  265. PAGE A, Paoli P, Moran Salvador E, White S, et al
    Hepatic Stellate Cell Transdifferentiation Involves Genome-Wide Remodeling of the DNA Methylation Landscape.
    J Hepatol. 2015 Nov 26. pii: S0168-8278(15)00782.
    PubMed     Text format     Abstract available


  266. VERMA VK, Li H, Wang R, Hirsova P, et al
    Alcohol stimulates macrophage activation through caspase dependent hepatocyte derived release of CD40L containing extracellular vesicles.
    J Hepatol. 2015 Nov 26. pii: S0168-8278(15)00778.
    PubMed     Text format     Abstract available


  267. RAY KIM W, Berg T, Asselah T, Flisiak R, et al
    Evaluation of APRI and FIB-4 scoring systems for non-invasive assessment of hepatic fibrosis in chronic hepatitis B patients.
    J Hepatol. 2015 Nov 25. pii: S0168-8278(15)00770.
    PubMed     Text format     Abstract available


  268. HELSEN N, Debing Y, Paeshuyse J, Dallmeier K, et al
    Stem cell-derived hepatocytes: a novel model for hepatitis E virus replication.
    J Hepatol. 2015 Nov 25. pii: S0168-8278(15)00771.
    PubMed     Text format     Abstract available


  269. GOVAERE O, Wouters J, Petz M, Vandewynckel YP, et al
    Laminin-332 sustains chemoresistance and quiescence as part of the human hepatic cancer stem cell niche.
    J Hepatol. 2015 Nov 17. pii: S0168-8278(15)00744.
    PubMed     Text format     Abstract available



  270. EASL Clinical Practice Guidelines: Liver transplantation.
    J Hepatol. 2015 Nov 17. pii: S0168-8278(15)00677.
    PubMed     Text format    


  271. NEVZOROVA YA, Cubero FJ, Hu W, Hao F, et al
    Enhanced expression of c-myc in hepatocytes promotes initiation and progression of alcoholic liver disease.
    J Hepatol. 2015 Nov 11. pii: S0168-8278(15)00735.
    PubMed     Text format     Abstract available


  272. EGUCHI A, Jeu XM, Johnson CD, Nektaria A, et al
    Liver Bid-suppression for treatment of fibrosis associated with nonalcoholic steatohepatitis.
    J Hepatol. 2015 Nov 7. pii: S0168-8278(15)00732.
    PubMed     Text format     Abstract available


  273. PANG Q, Zhang JY, Liu SS, Liu C, et al
    Adverse effects of platelets on posthepatectomy outcomes in patients with hepatocellular carcinoma.
    J Hepatol. 2015 Nov 6. pii: S0168-8278(15)00727.
    PubMed     Text format    


  274. LIU PH, Hsu CY, Hsia CY, Lee YH, et al
    Prognosis of Hepatocellular Carcinoma: Assessment of Eleven Staging Systems.
    J Hepatol. 2015 Nov 6. pii: S0168-8278(15)00730.
    PubMed     Text format     Abstract available


  275. ROWE IA, Sherman M
    Capitalising on improved rates of diagnosis of early hepatocellular carcinoma.
    J Hepatol. 2015 Nov 6. pii: S0168-8278(15)00728.
    PubMed     Text format    


    October 2015
  276. NADIM MK, Durand F, Kellum JA, Levitsky J, et al
    Management of the Critically Ill Patient with Cirrhosis: A Multidisciplinary Perspective.
    J Hepatol. 2015 Oct 28. pii: S0168-8278(15)00718.
    PubMed     Text format    


  277. ORO D, Yudina T, Fernandez-Varo G, Casals E, et al
    Cerium oxide nanoparticles reduce steatosis, portal hypertension and display antiinflammatory properties in rats with liver fibrosis.
    J Hepatol. 2015 Oct 28. pii: S0168-8278(15)00719.
    PubMed     Text format     Abstract available


  278. YANG T, Lu JH, Lau WY, Zhang TY, et al
    Perioperative Blood Transfusion Does Not Influence Recurrence-free and Overall Survivals after Curative Resection for Hepatocellular Carcinoma: A Propensity Score Matching Analysis.
    J Hepatol. 2015 Oct 24. pii: S0168-8278(15)00711.
    PubMed     Text format     Abstract available


  279. SHINDOH J, Makuuchi M, Matsuyama Y, Mise Y, et al
    Complete removal of the tumor-bearing portal territory decreases local tumor recurrence and improves disease-specific survival of patients with hepatocellular carcinoma.
    J Hepatol. 2015 Oct 23. pii: S0168-8278(15)00714.
    PubMed     Text format     Abstract available


  280. FELD JJ, Moreno C, Trinh R, Tam E, et al
    Sustained Virologic Response of 100% in HCV Genotype 1b Patients with Cirrhosis Receiving Ombitasvir/Paritaprevir/r and Dasabuvir for 12 Weeks.
    J Hepatol. 2015 Oct 14. pii: S0168-8278(15)00676.
    PubMed     Text format     Abstract available


  281. LI L, Pilo GM, Li X, Cigliano A, et al
    Inactivation of fatty acid synthase impairs hepatocarcinogenesis driven by AKT in mice and humans.
    J Hepatol. 2015 Oct 14. pii: S0168-8278(15)00675.
    PubMed     Text format     Abstract available


  282. CHUNG SI, Moon H, Ju HL, Cho KJ, et al
    Hepatic expression of Sonic Hedgehog induces liver fibrosis and promotes hepatocarcinogenesis in a transgenic mouse model.
    J Hepatol. 2015 Oct 12. pii: S0168-8278(15)00678.
    PubMed     Text format     Abstract available


  283. FARAH BL, Landau DJ, Sinha RA, Brooks ED, et al
    Induction of autophagy improves hepatic lipid metabolism in glucose-6-phosphatase deficiency.
    J Hepatol. 2015 Oct 10. pii: S0168-8278(15)00679.
    PubMed     Text format     Abstract available


  284. LIU HX, Rocha CS, Dandekar S, Wan YY, et al
    Functional analysis of the relationship between intestinal microbiota and the expression of hepatic genes and pathways during the course of liver regeneration.
    J Hepatol. 2015 Oct 7. pii: S0168-8278(15)00670.
    PubMed     Text format     Abstract available


  285. ATHYROS VG, Katsiki N, Karagiannis A, Mikhailidis DP, et al
    Statins and non-alcoholic steatohepatitis.
    J Hepatol. 2015 Oct 6. pii: S0168-8278(15)00668.
    PubMed     Text format    


  286. DONGIOVANNI P, Pihlajamaki J, Romeo S, Valenti L, et al
    Statin treatment for nonalcoholic steatohepatitis.
    J Hepatol. 2015 Oct 6. pii: S0168-8278(15)00671.
    PubMed     Text format    


  287. DHANASEKARAN R, Venkatesh SK, Torbenson M, Roberts LR, et al
    Clinical Implications of Basic Research in Hepatocellular Carcinoma.
    J Hepatol. 2015 Oct 5. pii: S0168-8278(15)00626.
    PubMed     Text format    


  288. LEROY V, Asselah T
    Universal hepatitis B vaccination: the only way to eliminate hepatocellular carcinoma?
    J Hepatol. 2015 Oct 5. pii: S0168-8278(15)00667.
    PubMed     Text format    


  289. XU JF, Liu XY
    PIVKA-II is an independent prognostic factor for overall survival of HCC patients and maybe associated with epithelial-mesenchymal transition.
    J Hepatol. 2015;63:1040-1.
    PubMed     Text format    


    September 2015
  290. LIANG HW, Wang N, Wang Y, Wang F, et al
    Hepatitis B virus-human chimeric transcript HBx-LINE1 promotes hepatic injury via sequestering cellular microRNA-122.
    J Hepatol. 2015 Sep 23. pii: S0168-8278(15)00631.
    PubMed     Text format     Abstract available


  291. PARK YK, Park ES, Kim DH, Ahn SH, et al
    Cleaved c-FLIP mediates the antiviral effect of TNF-alpha against hepatitis B virus by dysregulating hepatocyte nuclear factors.
    J Hepatol. 2015 Sep 23. pii: S0168-8278(15)00630.
    PubMed     Text format     Abstract available


  292. ZHANG X, Han J, Man K, Li X, et al
    CXC chemokine receptor 3 promotes steatohepatitis in mice through mediating inflammatory cytokines, macrophage and autophagy.
    J Hepatol. 2015 Sep 19. pii: S0168-8278(15)00621.
    PubMed     Text format     Abstract available


  293. YAN M, Ha J, Aguilar M, Bhuket T, et al
    Birth Cohort-Specific Disparities in Hepatocellular Carcinoma Stage at Diagnosis, Treatment, and Long-term Survival.
    J Hepatol. 2015 Sep 16. pii: S0168-8278(15)00623.
    PubMed     Text format     Abstract available


  294. BEUERS U, Gershwin ME, Gish RG, Invernizzi P, et al
    Changing nomenclature for PBC: From 'cirrhosis' to 'cholangitis'.
    J Hepatol. 2015 Sep 10. pii: S0168-8278(15)00459.
    PubMed     Text format    


  295. KOHLER UA, Bohm F, Rolfs F, Egger M, et al
    NF-kappaB/RelA and Nrf2 cooperate to maintain hepatocyte integrity and to prevent development of hepatocellular adenoma.
    J Hepatol. 2015 Sep 5. pii: S0168-8278(15)00613.
    PubMed     Text format     Abstract available


  296. KHATRI A, Menon R
    Reply to comments on: Pharmacokinetics and Safety of Coadministered Paritaprevir plus Ritonavir (Paritaprevir/r), Ombitasvir, and Dasabuvir in Hepatic Impairment.
    J Hepatol. 2015 Sep 5. pii: S0168-8278(15)00612.
    PubMed     Text format    


  297. SCIARRA A, Di Tommaso L, Nakano M, Destro A, et al
    Morphophenotypic changes in human multistep hepatocarcinogenesis with translational implications.
    J Hepatol. 2015 Sep 4. pii: S0168-8278(15)00611.
    PubMed     Text format     Abstract available


  298. CHTIOUI H, Buclin T
    Pharmacokinetics and Safety of Coadministered Paritaprevir plus Ritonavir (Paritaprevir/r), Ombitasvir, and Dasabuvir in Hepatic Impairment.
    J Hepatol. 2015 Sep 4. pii: S0168-8278(15)00610.
    PubMed     Text format    


  299. SARAN U, Humar B, Kolly P, Dufour JF, et al
    Hepatocellular Carcinoma and Lifestyles.
    J Hepatol. 2015 Sep 1. pii: S0168-8278(15)00600.
    PubMed     Text format     Abstract available


  300. EGGENHOFER E, Sabet-Rashedi M, Lantow M, Renner P, et al
    RORgammat IL-22-producing NKp46 cells protect from hepatic ischemia reperfusion injury in mice.
    J Hepatol. 2015 Sep 1. pii: S0168-8278(15)00595.
    PubMed     Text format     Abstract available


  301. GALBOIS A, Maury E, Guidet B, Ait-Oufella H, et al
    Reply to: "Is skin mottling a predictor of high mortality in non-selected patients with cirrhosis admitted to intensive care unit?".
    J Hepatol. 2015;63:772-3.
    PubMed     Text format    


  302. CASSINOTTO C, de Ledinghen V
    Reply to: "New imaging assisted methods for liver fibrosis quantification: Is it really favorable to classical transient elastography?".
    J Hepatol. 2015;63:767.
    PubMed     Text format    


  303. LANTHIER N, Starkel P, Horsmans Y
    New imaging assisted methods for liver fibrosis quantification: Is it really favorable to classical transient elastography?
    J Hepatol. 2015;63:765-6.
    PubMed     Text format    


    August 2015
  304. LEI XF, Fu W, Kim-Kaneyama JR, Omoto T, et al
    Hic-5 deficiency attenuates the activation of hepatic stellate cells and liver fibrosis through upregulation of Smad7 in mice.
    J Hepatol. 2015 Aug 31. pii: S0168-8278(15)00598.
    PubMed     Text format     Abstract available


  305. MORATALLA A, Caparros E, Juanola O, Portune K, et al
    Bifidobacterium pseudocatenulatum CECT7765 induces an M2 anti-inflammatory transition in macrophages from patients with cirrhosis.
    J Hepatol. 2015 Aug 31. pii: S0168-8278(15)00592.
    PubMed     Text format     Abstract available


  306. BUREAU C, Laurent J, Robic MA, Christol C, et al
    Central obesity is associated with non-cirrhotic portal-vein thrombosis.
    J Hepatol. 2015 Aug 31. pii: S0168-8278(15)00596.
    PubMed     Text format     Abstract available


  307. HU J, Zhu XH, Zhang XJ, Wang PX, et al
    Targeting TRAF3 signaling protects against hepatic ischemia/reperfusions injury.
    J Hepatol. 2015 Aug 31. pii: S0168-8278(15)00593.
    PubMed     Text format     Abstract available


  308. CUCCHETTI A, Cescon M, Golfieri R, Piscaglia F, et al
    Hepatic venous pressure gradient in the preoperative assessment of patients with resectable hepatocellular carcinoma.
    J Hepatol. 2015 Aug 29. pii: S0168-8278(15)00597.
    PubMed     Text format     Abstract available


  309. SHELDON RD, Nicole Blaize A, Fletcher JA, Pearson KJ, et al
    Gestational exercise protects adult male offspring from high-fat diet induced hepatic steatosis.
    J Hepatol. 2015 Aug 29. pii: S0168-8278(15)00594.
    PubMed     Text format     Abstract available


  310. RAUTOU PE, Tatsumi K, Antoniak S, Owens AP 3rd, et al
    Hepatocyte Tissue Factor Contributes to the Hypercoagulable State in a Mouse Model of Chronic Liver Injury.
    J Hepatol. 2015 Aug 29. pii: S0168-8278(15)00588.
    PubMed     Text format     Abstract available


  311. DE VRIES AG, Bakker-van Waarde WM, Dassel AC, Losekoot M, et al
    A novel phenotype of a hepatocyte nuclear factor homeobox A (HNF1A) gene mutation, presenting with neonatal cholestasis.
    J Hepatol. 2015 Aug 22. pii: S0168-8278(15)00543.
    PubMed     Text format     Abstract available


  312. EHLTING C, Trilling M, Tiedje C, Le-Trilling VT, et al
    MAPKAP kinase 2 regulates IL-10 expression and prevents formation of intrahepatic myeloid cell aggregates during cytomegalovirus infections.
    J Hepatol. 2015 Aug 20. pii: S0168-8278(15)00554.
    PubMed     Text format     Abstract available


  313. KAMATH PS, Poterucha JJ, Ludwig J
    Primary Biliary Cirrhosis by Another Name is Still PBC.
    J Hepatol. 2015 Aug 19. pii: S0168-8278(15)00555.
    PubMed     Text format    


  314. GRANCINI V, Trombetta M, Lunati ME, Zimbalatti D, et al
    Contribution of beta-cell dysfunction and insulin resistance to cirrhosis-associated diabetes: role of severity of liver disease.
    J Hepatol. 2015 Aug 19. pii: S0168-8278(15)00553.
    PubMed     Text format     Abstract available


  315. BOSCH A, Dumortier J, Maucort-Boulch D, Scoazec JY, et al
    Preventive administration of UDCA after liver transplantation for primary biliary cirrhosis is associated with a lower risk of disease recurrence.
    J Hepatol. 2015 Aug 14. pii: S0168-8278(15)00545.
    PubMed     Text format     Abstract available


  316. LI J, Huang Q, Long X, Zhang J, et al
    CD147 reprograms fatty acid metabolism in hepatocellularcarcinoma cells through Akt/mTOR/SREBP1cand P38/PPARalpha pathways.
    J Hepatol. 2015 Aug 14. pii: S0168-8278(15)00546.
    PubMed     Text format     Abstract available


  317. LEE KC, Lin HC, Huang YH, Hung SC, et al
    Allo-transplantation of Mesenchymal Stem Cells Attenuates Hepatic Injury through IL1Ra Dependent Macrophage Switch in a Mouse Model of Liver Disease.
    J Hepatol. 2015 Aug 11. pii: S0168-8278(15)00538.
    PubMed     Text format     Abstract available


  318. HUNG GY, Horng JL, Yen HJ, Lee CY, et al
    Changing Incidence Patterns of Hepatocellular Carcinoma Among Age Groups in Taiwan.
    J Hepatol. 2015 Aug 6. pii: S0168-8278(15)00534.
    PubMed     Text format     Abstract available


  319. NOJIMA H, Freeman CM, Schuster RM, Japtok L, et al
    Hepatocyte exosomes mediate liver repair and regeneration via sphingosine-1-phosphate.
    J Hepatol. 2015 Aug 5. pii: S0168-8278(15)00531.
    PubMed     Text format     Abstract available


  320. KAN QC, Cui XW, Chang JM, Dietrich CF, et al
    Strain ultrasound elastography for liver diseases.
    J Hepatol. 2015;63:534.
    PubMed     Text format    


  321. VAN BEERS BE
    Reply to: "Strain ultrasound elastography for liver diseases".
    J Hepatol. 2015;63:535.
    PubMed     Text format    


    July 2015
  322. KODA M, Tokunaga S, Okamoto T, Hodozuka M, et al
    Clinical usefulness of the ablative margin assessed by magnetic resonance imaging with Gd-EOB-DTPA for radiofrequency ablation of hepatocellular carcinoma.
    J Hepatol. 2015 Jul 28. pii: S0168-8278(15)00514.
    PubMed     Text format     Abstract available


  323. MILTIADOUS O, Sia D, Hoshida Y, Fiel MI, et al
    Progenitor cell markers predict outcome of patients with Hepatocellular Carcinoma beyond Milan criteria undergoing liver transplantation.
    J Hepatol. 2015 Jul 25. pii: S0168-8278(15)00516.
    PubMed     Text format     Abstract available


  324. ZHENG Z, Zhang X, Wang J, Dandeka A, et al
    Exposure to Fine Airborne Particulate Matters Induces Hepatic Fibrosis in Murine Models.
    J Hepatol. 2015 Jul 25. pii: S0168-8278(15)00511.
    PubMed     Text format     Abstract available


  325. TODD STRAVITZ R, Reuben A, Mizrahi M, Lalazar G, et al
    Use of the Methacetin Breath Test to Classify the Risk of Cirrhotic Complications and Mortality in Patients Evaluated/Listed for Liver Transplantation.
    J Hepatol. 2015 Jul 25. pii: S0168-8278(15)00512.
    PubMed     Text format     Abstract available


  326. LUANGSAY S, Gruffaz M, Isorce N, Testoni B, et al
    Early Inhibition of Hepatocyte Innate Responses by Hepatitis B Virus.
    J Hepatol. 2015 Jul 24. pii: S0168-8278(15)00477.
    PubMed     Text format     Abstract available


  327. BERZIGOTTI A, Boyer TD, Castera L, de Franchis R, et al
    Reply to "Points to be considered when using transient elastography for diagnosis of portal hypertension according to the Baveno's VI consensus".
    J Hepatol. 2015 Jul 23. pii: S0168-8278(15)00475.
    PubMed     Text format    


  328. HSIANG JC, Wong GL, Tse YK, Wong VW, et al
    Statin and the risk of hepatocellular carcinoma and death in a hospital-based hepatitis B-infected population: a propensity-score landmark analysis.
    J Hepatol. 2015 Jul 21. pii: S0168-8278(15)00472.
    PubMed     Text format     Abstract available


  329. JEPSEN P, Watson H, Andersen PK, Vilstrup H, et al
    Diabetes as a risk factor for hepatic encephalopathy in cirrhosis patients.
    J Hepatol. 2015 Jul 20. pii: S0168-8278(15)00470.
    PubMed     Text format     Abstract available


  330. PERAZZO H, Fernandes FF, Castro Filho EC, Perez RM, et al
    Points to be considered when using transient elastography for diagnosis of portal hypertension according to the Baveno's VI consensus.
    J Hepatol. 2015 Jul 20. pii: S0168-8278(15)00468.
    PubMed     Text format    


  331. YANG YH, Chen WC, Tsan YT, Chen MJ, et al
    Statin use and the risk of cirrhosis development in patients with hepatitis C virus infection.
    J Hepatol. 2015 Jul 18. pii: S0168-8278(15)00469.
    PubMed     Text format     Abstract available


  332. BERNARDI M, Moreau R, Angeli P, Schnabl B, et al
    Mechanisms of Decompensation and Organ Failure in Cirrhosis: From Peripheral arterial Vasodilation to Systemic Inflammation Hypothesis.
    J Hepatol. 2015 Jul 17. pii: S0168-8278(15)00466.
    PubMed     Text format     Abstract available


  333. KAMATH PS, Mookerjee R
    Individualized Care for Portal Hypertension: Not quite yet.
    J Hepatol. 2015 Jul 3. pii: S0168-8278(15)00455.
    PubMed     Text format    


  334. CHERQUI D
    Laparoscopic Liver Resection: A New Paradigm in the Management of Hepatocellular Carcinoma?
    J Hepatol. 2015 Jul 2. pii: S0168-8278(15)00456.
    PubMed     Text format    


    June 2015
  335. SEMPOUX C, Paradis V, Komuta M, Wee A, et al
    Hepatocellular nodules expressing markers of hepatocellular adenomas in Budd- Chiari syndrome and other rare hepatic vascular disorders.
    J Hepatol. 2015 Jun 25. pii: S0168-8278(15)00409.
    PubMed     Text format     Abstract available


  336. GISSEN P, Arias IM
    Structural and Functional Hepatocyte Polarity and Liver Disease.
    J Hepatol. 2015 Jun 24. pii: S0168-8278(15)00407.
    PubMed     Text format     Abstract available


  337. VAN MEER S, de Man RA, Coenraad MJ, Sprengers D, et al
    Surveillance for hepatocellular carcinoma is associated with increased survival: Results from a large cohort in the Netherlands.
    J Hepatol. 2015 Jun 19. pii: S0168-8278(15)00403.
    PubMed     Text format     Abstract available


  338. FERENCI P, Kozbial K, Mandorfer M, Hofer H, et al
    HCV targeting of patients with cirrhosis.
    J Hepatol. 2015 Jun 19. pii: S0168-8278(15)00393.
    PubMed     Text format     Abstract available


  339. IRACHETA-VELLVE A, Petrasek J, Satishchandran A, Gyongyosi B, et al
    Inhibition of sterile danger signals, uric acid and ATP, prevents inflammasome activation and protects from alcoholic steatohepatitis in mice.
    J Hepatol. 2015 Jun 19. pii: S0168-8278(15)00405.
    PubMed     Text format     Abstract available


  340. LAMPERTICO P, Invernizzi F, Vigano M, Loglio A, et al
    The long-term benefits of nucleos(t)ide analogs on esophageal varices in compensated HBV cirrhotics with no or small esophageal varices: A 12-year prospective cohort study.
    J Hepatol. 2015 Jun 19. pii: S0168-8278(15)00397.
    PubMed     Text format     Abstract available


  341. NIO K, Yamashita T, Okada H, Kondo M, et al
    Defeating EpCAM liver cancer stem cells by targeting chromatin remodeling enzyme CHD4 in human hepatocellular carcinoma.
    J Hepatol. 2015 Jun 18. pii: S0168-8278(15)00400.
    PubMed     Text format     Abstract available


  342. ALEXOPOULOU A, Vasilieva L, Agiasotelli D, Dourakis SP, et al
    Fungal Infections in patients with cirrhosis.
    J Hepatol. 2015 Jun 18. pii: S0168-8278(15)00396.
    PubMed     Text format    


  343. ALMISHRI W, Deans J, Swain MG
    Rapid activation and hepatic recruitment of innate-like regulatory B cells after invariant NKT cell stimulation in mice.
    J Hepatol. 2015 Jun 18. pii: S0168-8278(15)00398.
    PubMed     Text format     Abstract available


  344. CHENG AL, Kang YK, He AR, Lim HY, et al
    Safety and efficacy of tigatuzumab plus sorafenib as first-line therapy in subjects with advanced hepatocellular carcinoma: a phase 2 randomized study.
    J Hepatol. 2015 Jun 10. pii: S0168-8278(15)00390.
    PubMed     Text format     Abstract available


  345. KHATRI A, Menon R, Marbury TC, Lawitz E, et al
    Pharmacokinetics and Safety of Coadministered Paritaprevir plus Ritonavir (Paritaprevir/r), Ombitasvir, and Dasabuvir in Hepatic Impairment.
    J Hepatol. 2015 Jun 10. pii: S0168-8278(15)00387.
    PubMed     Text format     Abstract available


  346. MAZZA G, De Coppi P, Gissen P, Pinzani M, et al
    Hepatic regenerative medicine.
    J Hepatol. 2015 Jun 9. pii: S0168-8278(15)00323.
    PubMed     Text format    


  347. COUDROY R, Jamet A, Thille AW
    Is skin mottling a predictor of high mortality in non-selected patients with cirrhosis admitted to intensive care unit?
    J Hepatol. 2015 Jun 5. pii: S0168-8278(15)00383.
    PubMed     Text format    


  348. DE FRANCHIS R
    EXPANDING CONSENSUS IN PORTAL HYPERTENSION Report of the Baveno VI Consensus Workshop: stratifying risk and individualizing care for portal hypertension.
    J Hepatol. 2015 Jun 2. pii: S0168-8278(15)00349.
    PubMed     Text format    


  349. MUNOZ-GARRIDO P, Marin JJ, Perugorria MJ, Urribarri AD, et al
    Ursodeoxycholic Acid Inhibits Hepatic Cystogenesis in Experimental Models of Polycystic Liver Disease.
    J Hepatol. 2015 Jun 1. pii: S0168-8278(15)00350.
    PubMed     Text format     Abstract available


  350. BUSCHOW SI, Sprengers D, Woltman AM
    To target or not to target viral antigens in HBV related HCC?
    J Hepatol. 2015;62:1449-50.
    PubMed     Text format    


  351. QASIM W, Brunetto M, Gehring AJ, Maini MK, et al
    Reply to: "To target or not to target viral antigens in HBV related HCC?".
    J Hepatol. 2015;62:1450-2.
    PubMed     Text format    


  352. PERRA A, Kowalik MA, Giordano S, Columbano A, et al
    Reply to: "YAP in tumorigenesis: Friend or foe?".
    J Hepatol. 2015;62:1445.
    PubMed     Text format    


  353. LIU S, Pang Q, Zhang J, Liu C, et al
    YAP in tumorigenesis: Friend or foe?
    J Hepatol. 2015;62:1444.
    PubMed     Text format    


  354. ADHOUTE X, Penaranda G, Raoul JL, Bourliere M, et al
    Reply to: ''Repeated transarterial chemoembolization: An overfitting effort?''.
    J Hepatol. 2015;62:1442-3.
    PubMed     Text format    


  355. FACCIORUSSO A, Bhoori S, Sposito C, Mazzaferro V, et al
    Repeated transarterial chemoembolization: An overfitting effort?
    J Hepatol. 2015;62:1440-2.
    PubMed     Text format    


  356. YU WL, Sun Y
    Interferon regulatory factor 9 plays a dual function in health and disease.
    J Hepatol. 2015;62:1446.
    PubMed     Text format    


  357. ZHANG XJ, Wang PX, Zhang P, Li H, et al
    Reply to: "Interferon regulatory factor 9 plays a dual function in health and disease".
    J Hepatol. 2015;62:1447-8.
    PubMed     Text format    


    May 2015
  358. FU WM, Zhu X, Wang WM, Lu YF, et al
    Hotair Mediates Hepatocarcinogenesis through Suppressing MiRNA-218 Expression and Activating P14 and P16 Signaling.
    J Hepatol. 2015 May 26. pii: S0168-8278(15)00343.
    PubMed     Text format     Abstract available


  359. YADA A, Iimuro Y, Uyama N, Uda Y, et al
    Splenectomy attenuates murine liver fibrosis with hypersplenism stimulating hepatic accumulation of Ly-6C macrophages.
    J Hepatol. 2015 May 25. pii: S0168-8278(15)00337.
    PubMed     Text format     Abstract available


  360. GODOY P, Schmidt-Heck W, Natarajan K, Lucendo-Villarin B, et al
    Gene networks and transcription factor motifs defining the differentiation of stem cells into hepatocyte-like cells.
    J Hepatol. 2015 May 25. pii: S0168-8278(15)00340.
    PubMed     Text format     Abstract available


  361. FARRAR CT, DePeralta DK, Day H, Rietz TA, et al
    3D molecular MR imaging of liver fibrosis and response to rapamycin therapy in a bile duct ligation rat model.
    J Hepatol. 2015 May 25. pii: S0168-8278(15)00335.
    PubMed     Text format     Abstract available


  362. DA SILVA MIOZZO SA, Tovo CV, John JA, de Mattos AA, et al
    Proton pump inhibitor use and spontaneous bacterial peritonitis in cirrhosis: an undesirable association?
    J Hepatol. 2015 May 23. pii: S0168-8278(15)00334.
    PubMed     Text format    


  363. FANG F, Chang RM, Yu L, Lei X, et al
    MicroRNA-188-5p Suppresses Tumor Cell Proliferation and Metastasis by Directly Targeting FGF5 in Hepatocellular Carcinoma.
    J Hepatol. 2015 May 18. pii: S0168-8278(15)00331.
    PubMed     Text format     Abstract available


  364. THEVENOT T, Monnet E, Di Martino V
    Reply to "Albumin infusion in cirrhotic patients with non-SBP infections: end of the story?"
    J Hepatol. 2015 May 18. pii: S0168-8278(15)00330.
    PubMed     Text format    


  365. MERLI M, Lucidi C, Lattanzi B, Riggio O, et al
    Albumin infusion in cirrhotic patients with infections other than Spontaneous Bacterial Peritonitis: end of the story?
    J Hepatol. 2015 May 16. pii: S0168-8278(15)00329.
    PubMed     Text format    


  366. XIA H, Jianxiang C, Shi M, Gao H, et al
    EDIL3 is a novel regulator of epithelial mesenchymal transition controlling early recurrence of hepatocellular carcinoma.
    J Hepatol. 2015 May 13. pii: S0168-8278(15)00327.
    PubMed     Text format     Abstract available


  367. DONGIOVANNI P, Petta S, Mannisto V, Margherita Mancina R, et al
    Statin use and nonalcoholic steatohepatitis in at risk individuals.
    J Hepatol. 2015 May 13. pii: S0168-8278(15)00328.
    PubMed     Text format     Abstract available


  368. MORIYA A, Iwasaki Y, Ohguchi S, Yamamoto K, et al
    Reply to: "protective effects of moderate alcohol consumption on fatty liver: a spurious association?".
    J Hepatol. 2015;62:1211-2.
    PubMed     Text format    


  369. BELL S, Britton A
    Protective effects of moderate alcohol consumption on fatty liver: a spurious association?
    J Hepatol. 2015;62:1209-11.
    PubMed     Text format    


  370. ULUCAN S, Katlandur H, Kaya Z
    Epicardial fat and liver disease; the contribution of cardio autonomic nervous system function.
    J Hepatol. 2015;62:1214.
    PubMed     Text format    


  371. CORRAO S, Rinollo C, Scaglione R
    Non-alcoholic fatty liver disease: severity of fibrosis and its relationships with clinical and biological variables.
    J Hepatol. 2015;62:1212-3.
    PubMed     Text format    


  372. PETTA S, Craxi A
    Epicardial fat in patients with non-alcoholic fatty liver disease.
    J Hepatol. 2015;62:1215.
    PubMed     Text format    


  373. ADAMS LA, Ratziu V
    Non-alcoholic fatty liver - perhaps not so benign.
    J Hepatol. 2015;62:1002-4.
    PubMed     Text format    


  374. SIEGHART W, Hucke F, Peck-Radosavljevic M
    Transarterial chemoembolization: modalities, indication, and patient selection.
    J Hepatol. 2015;62:1187-95.
    PubMed     Text format     Abstract available


  375. LONDONO MC, Abraldes JG, Altamirano J, Decaens T, et al
    Clinical trial watch: reports from the AASLD Liver Meeting(R), Boston, November 2014.
    J Hepatol. 2015;62:1196-203.
    PubMed     Text format     Abstract available


  376. KARIMI K, Kessler T, Thiele K, Ramisch K, et al
    Prenatal acetaminophen induces liver toxicity in dams, reduces fetal liver stem cells, and increases airway inflammation in adult offspring.
    J Hepatol. 2015;62:1085-91.
    PubMed     Text format     Abstract available


  377. INAGAKI NF, Inagaki FF, Kokudo N, Miyajima A, et al
    Use of mouse liver mesothelial cells to prevent postoperative adhesion and promote liver regeneration after hepatectomy.
    J Hepatol. 2015;62:1141-7.
    PubMed     Text format     Abstract available


  378. RYU S, Chang Y, Choi Y, Kwon MJ, et al
    Age at menarche and non-alcoholic fatty liver disease.
    J Hepatol. 2015;62:1164-70.
    PubMed     Text format     Abstract available


    April 2015
  379. ANSTEE QM, Liu YL, Day CP, Reeves HL, et al
    Reply to: HCC and liver disease risk in homozygous PNPLA3 p.I148M carriers approach monogenic inheritance.
    J Hepatol. 2015;62:982-3.
    PubMed     Text format    


  380. KRAWCZYK M, Stokes CS, Romeo S, Lammert F, et al
    HCC and liver disease risks in homozygous PNPLA3 p.I148M carriers approach monogenic inheritance.
    J Hepatol. 2015;62:980-1.
    PubMed     Text format    


  381. TEMMERMAN F, Nevens F
    Reply to: "Development and validation of a polycystic liver disease complaint-specific assessment (POLCA) - use of the Delphi technique for content validation".
    J Hepatol. 2015;62:989.
    PubMed     Text format    


  382. TREVISOL DJ, da Silva A, de Souza F, Zapelini CM, et al
    Development and validation of a polycystic liver disease complaint-specific assessment (POLCA) - use of the Delphi technique for content validation.
    J Hepatol. 2015;62:988.
    PubMed     Text format    


  383. BIRERDINC A, Younossi Z
    Can NASH lipidome provide insight into the pathogenesis of obesity-related non-alcoholic fatty liver disease?
    J Hepatol. 2015;62:761-2.
    PubMed     Text format    


  384. VAN GOLEN RF, Reiniers MJ, Heger M, Verheij J, et al
    Solutions to the discrepancies in the extent of liver damage following ischemia/reperfusion in standard mouse models.
    J Hepatol. 2015;62:975-7.
    PubMed     Text format    


  385. ADHOUTE X, Penaranda G, Naude S, Raoul JL, et al
    Retreatment with TACE: the ABCR SCORE, an aid to the decision-making process.
    J Hepatol. 2015;62:855-62.
    PubMed     Text format     Abstract available


  386. GARCIA-MARTINEZ R, Andreola F, Mehta G, Poulton K, et al
    Immunomodulatory and antioxidant function of albumin stabilises the endothelium and improves survival in a rodent model of chronic liver failure.
    J Hepatol. 2015;62:799-806.
    PubMed     Text format     Abstract available


  387. ANJANI K, Lhomme M, Sokolovska N, Poitou C, et al
    Circulating phospholipid profiling identifies portal contribution to NASH signature in obesity.
    J Hepatol. 2015;62:905-12.
    PubMed     Text format     Abstract available


  388. BOURSIER J, de Ledinghen V, Poynard T, Guechot J, et al
    An extension of STARD statements for reporting diagnostic accuracy studies on liver fibrosis tests: the Liver-FibroSTARD standards.
    J Hepatol. 2015;62:807-15.
    PubMed     Text format     Abstract available


  389. PETTA S, Argano C, Colomba D, Camma C, et al
    Epicardial fat, cardiac geometry and cardiac function in patients with non-alcoholic fatty liver disease: association with the severity of liver disease.
    J Hepatol. 2015;62:928-33.
    PubMed     Text format     Abstract available


  390. MORIYA A, Iwasaki Y, Ohguchi S, Kayashima E, et al
    Roles of alcohol consumption in fatty liver: a longitudinal study.
    J Hepatol. 2015;62:921-7.
    PubMed     Text format     Abstract available


  391. LAZO M, Rubin J, Clark JM, Coresh J, et al
    The association of liver enzymes with biomarkers of subclinical myocardial damage and structural heart disease.
    J Hepatol. 2015;62:841-7.
    PubMed     Text format     Abstract available


  392. RATZIU V, Goodman Z, Sanyal A
    Current efforts and trends in the treatment of NASH.
    J Hepatol. 2015;62.
    PubMed     Text format     Abstract available


  393. KARLSEN TH, Lammert F, Thompson RJ
    Genetics of liver disease: From pathophysiology to clinical practice.
    J Hepatol. 2015;62.
    PubMed     Text format     Abstract available


  394. BYRNE CD, Targher G
    NAFLD: a multisystem disease.
    J Hepatol. 2015;62.
    PubMed     Text format     Abstract available


  395. FORBES SJ, Gupta S, Dhawan A
    Cell therapy for liver disease: From liver transplantation to cell factory.
    J Hepatol. 2015;62.
    PubMed     Text format     Abstract available


  396. BRUIX J, Han KH, Gores G, Llovet JM, et al
    Liver cancer: Approaching a personalized care.
    J Hepatol. 2015;62.
    PubMed     Text format    


  397. BERNAL W, Lee WM, Wendon J, Larsen FS, et al
    Acute liver failure: A curable disease by 2024?
    J Hepatol. 2015;62.
    PubMed     Text format     Abstract available


    March 2015
  398. WONG F, O'Leary JG, Reddy KR, Kamath PS, et al
    A cut-off serum creatinine value of 1.5 mg/dl for AKI--to be or not to be.
    J Hepatol. 2015;62:741-3.
    PubMed     Text format    


  399. FAGUNDES C, Barreto R, Rodriguez E, Graupera I, et al
    Reply to: "A cut-off serum creatinine value of 1.5 mg/dl for AKI--to be or not to be".
    J Hepatol. 2015;62:743-4.
    PubMed     Text format    


  400. PIANO S, Tonon M, Cavallin M, Morando F, et al
    Reply to: "A cut-off serum creatinine value of 1.5 mg/dl for AKI--to be or not to be".
    J Hepatol. 2015;62:744-6.
    PubMed     Text format    


  401. LEI Y, Yee LW, Ping ZW
    Target patients for partial hepatectomy and relationship between PLT and prognosis in BCLC B HCC.
    J Hepatol. 2015;62:750.
    PubMed     Text format    


  402. LIU Y, Shao M, Wu Y, Yan C, et al
    Role for the endoplasmic reticulum stress sensor IRE1alpha in liver regenerative responses.
    J Hepatol. 2015;62:590-8.
    PubMed     Text format     Abstract available


  403. ZHOU Y, Llaurado G, Oresic M, Hyotylainen T, et al
    Circulating triacylglycerol signatures and insulin sensitivity in NAFLD associated with the E167K variant in TM6SF2.
    J Hepatol. 2015;62:657-63.
    PubMed     Text format     Abstract available


  404. MARTINEZ-UNA M, Varela-Rey M, Mestre D, Fernandez-Ares L, et al
    S-Adenosylmethionine increases circulating very-low density lipoprotein clearance in non-alcoholic fatty liver disease.
    J Hepatol. 2015;62:673-81.
    PubMed     Text format     Abstract available


  405. VAN BEERS BE, Daire JL, Garteiser P
    New imaging techniques for liver diseases.
    J Hepatol. 2015;62:690-700.
    PubMed     Text format     Abstract available


  406. MEIER RP, Mahou R, Morel P, Meyer J, et al
    Microencapsulated human mesenchymal stem cells decrease liver fibrosis in mice.
    J Hepatol. 2015;62:634-41.
    PubMed     Text format     Abstract available


  407. PAWLAK M, Lefebvre P, Staels B
    Molecular mechanism of PPARalpha action and its impact on lipid metabolism, inflammation and fibrosis in non-alcoholic fatty liver disease.
    J Hepatol. 2015;62:720-33.
    PubMed     Text format     Abstract available


  408. SCHNEIDER-YIN X, van Tuyll van Serooskerken AM, Siegesmund M, Went P, et al
    Biallelic inactivation of protoporphyrinogen oxidase and hydroxymethylbilane synthase is associated with liver cancer in acute porphyrias.
    J Hepatol. 2015;62:734-8.
    PubMed     Text format     Abstract available


  409. ALTROCK E, Sens C, Wuerfel C, Vasel M, et al
    Inhibition of fibronectin deposition improves experimental liver fibrosis.
    J Hepatol. 2015;62:625-33.
    PubMed     Text format     Abstract available


    January 2015
  410. MUELLER M, Thorell A, Claudel T, Jha P, et al
    Ursodeoxycholic Acid Exerts Farnesoid X Receptor-antagonistic Effects on Bile Acid and Lipid Metabolism in Morbid Obesity.
    J Hepatol. 2015 Jan 21. pii: S0168-8278(15)00010.
    PubMed     Text format     Abstract available


  411. MOREAU R, Bataller R, Berg T, Zucman-Rossi J, et al
    From the editor's desk ...
    J Hepatol. 2015;62:6-7.
    PubMed     Text format    


  412. PECK-RADOSAVLJEVIC M
    50 years of EASL--from a European to a global perspective.
    J Hepatol. 2015;62:4-5.
    PubMed     Text format    


  413. MARCHESINI G, Mazzotti A
    NAFLD incidence and remission: only a matter of weight gain and weight loss?
    J Hepatol. 2015;62:15-7.
    PubMed     Text format    


  414. DYSON JK, Webb G, Hirschfield GM, Lohse A, et al
    Unmet clinical need in autoimmune liver diseases.
    J Hepatol. 2015;62:208-18.
    PubMed     Text format     Abstract available


  415. WONG VW, Wong GL, Yeung DK, Lau TK, et al
    Incidence of non-alcoholic fatty liver disease in Hong Kong: a population study with paired proton-magnetic resonance spectroscopy.
    J Hepatol. 2015;62:182-9.
    PubMed     Text format     Abstract available


  416. ARGO CK, Patrie JT, Lackner C, Henry TD, et al
    Effects of n-3 fish oil on metabolic and histological parameters in NASH: a double-blind, randomized, placebo-controlled trial.
    J Hepatol. 2015;62:190-7.
    PubMed     Text format     Abstract available


  417. FORNER A, Vilana R, Bianchi L, Rodriguez-Lope C, et al
    Lack of arterial hypervascularity at contrast-enhanced ultrasound should not define the priority for diagnostic work-up of nodules <2 cm.
    J Hepatol. 2015;62:150-5.
    PubMed     Text format     Abstract available


  418. CUBERO FJ, Zhao G, Nevzorova YA, Hatting M, et al
    Haematopoietic cell-derived Jnk1 is crucial for chronic inflammation and carcinogenesis in an experimental model of liver injury.
    J Hepatol. 2015;62:140-9.
    PubMed     Text format     Abstract available


    December 2014
  419. MATZ-SOJA M, Gebhardt R
    The many faces of Hedgehog signalling in the liver: recent progress reveals striking cellular diversity and the importance of microenvironments.
    J Hepatol. 2014;61:1449-50.
    PubMed     Text format    


  420. GRZELAK CA, Sigglekow ND, Watkins DN, McCaughan GW, et al
    Reply to: "The many faces of Hedgehog signalling in the liver: recent progress reveals striking cellular diversity and the importance of microenvironments".
    J Hepatol. 2014;61:1451-2.
    PubMed     Text format    


    November 2014
  421. SARKAR M, Watt KD, Terrault N, Berenguer M, et al
    Outcomes in Liver Transplantation: Does Sex Matter?
    J Hepatol. 2014 Nov 26. pii: S0168-8278(14)00872.
    PubMed     Text format     Abstract available


    October 2014
  422. HAN S, Ha SY, Park CK, Joh JW, et al
    Microsteatosis may not interact with macrosteatosis in living donor liver transplantation.
    J Hepatol. 2014 Oct 27. pii: S0168-8278(14)00788.
    PubMed     Text format     Abstract available


  423. BOLOS D, Finn RS
    Systemic therapy in HCC: lessons from brivanib.
    J Hepatol. 2014;61:947-50.
    PubMed     Text format    


  424. SECKLEHNER J, Richardson CA
    The reporting of animal welfare details in liver research: A review of studies describing bile duct ligation in mice (2011-2013).
    J Hepatol. 2014 Oct 1. pii: S0168-8278(14)00720.
    PubMed     Text format    


    August 2014
  425. JIMENEZ-CASTRO MB, Merono N, Mendes-Braz M, Gracia-Sancho J, et al
    The Effect of Brain Death in Rat Steatotic and Non-Steatotic Liver Transplantation With Previous Ischemic Preconditioning.
    J Hepatol. 2014 Aug 8. pii: S0168-8278(14)00535.
    PubMed     Text format     Abstract available


    July 2014
  426. SHOUVAL D
    Expanding the donor pool for liver transplant recipients using HBsAg positive grafts.
    J Hepatol. 2014 Jul 16. pii: S0168-8278(14)00478.
    PubMed     Text format    


  427. PEREIRA-FANTINI PM, Lapthorne S, Joyce SA, Dellios NL, et al
    Altered FXR signaling is associated with bile acid dysmetabolism in short bowel syndrome-associated liver disease.
    J Hepatol. 2014 Jul 3. pii: S0168-8278(14)00455.
    PubMed     Text format     Abstract available


  428. ZHANG L, Schuppan D
    Traditional Chinese Medicine (TCM) for fibrotic liver disease: hope and hype.
    J Hepatol. 2014;61:166-8.
    PubMed     Text format    


  429. ROAYAIE S
    TACE vs. surgical resection for BCLC stage B HCC.
    J Hepatol. 2014;61:3-4.
    PubMed     Text format    


  430. TRIPODI A, Fracanzani AL, Primignani M, Chantarangkul V, et al
    Procoagulant imbalance in patients with non-alcoholic fatty liver disease.
    J Hepatol. 2014;61:148-54.
    PubMed     Text format     Abstract available


  431. HUCKE F, Sieghart W, Peck-Radosavljevic M
    Reply to the letters to the editor regarding the sequential ART-score.
    J Hepatol. 2014;61:177-8.
    PubMed     Text format    


  432. IRANMANESH P, Poncet A, Toso C
    Reply to: "virtual portal pressure from anatomic CT angiography".
    J Hepatol. 2014;61:182.
    PubMed     Text format    


  433. QI X, Xu M, Li Z, Yang C, et al
    Virtual portal pressure from anatomic CT angiography.
    J Hepatol. 2014;61:180-1.
    PubMed     Text format    


  434. CLARKE JD, Hardwick RN, Lake AD, Lickteig AJ, et al
    Synergistic interaction between genetics and disease on pravastatin disposition.
    J Hepatol. 2014;61:139-47.
    PubMed     Text format     Abstract available


    May 2014
  435. SHOUVAL D
    The emerging questionable benefit of Surafenib as a neo-adjuvant in HCC patients treated with Y-90 radioembolisation pending liver transplantation.
    J Hepatol. 2014 May 15. pii: S0168-8278(14)00353.
    PubMed     Text format    


  436. FRIEDMAN SL
    Replacing a crystal ball with a calculator in predicting liver disease outcomes.
    J Hepatol. 2014;60:905-6.
    PubMed     Text format    


  437. BERZIGOTTI A
    Getting closer to a point-of-care diagnostic assessment in patients with chronic liver disease: controlled attenuation parameter for steatosis.
    J Hepatol. 2014;60:910-2.
    PubMed     Text format    


  438. SUNG KC, Wild SH, Byrne CD
    Development of new fatty liver, or resolution of existing fatty liver, over five years of follow-up, and risk of incident hypertension.
    J Hepatol. 2014;60:1040-5.
    PubMed     Text format     Abstract available


  439. MCPHERSON S, Henderson E, Burt AD, Day CP, et al
    Serum immunoglobulin levels predict fibrosis in patients with non-alcoholic fatty liver disease.
    J Hepatol. 2014;60:1055-62.
    PubMed     Text format     Abstract available


  440. EGUCHI A, Wree A, Feldstein AE
    Biomarkers of liver cell death.
    J Hepatol. 2014;60:1063-74.
    PubMed     Text format     Abstract available


  441. KATO H, Kuriyama N, Duarte S, Clavien PA, et al
    MMP-9 deficiency shelters endothelial PECAM-1 expression and enhances regeneration of steatotic livers after ischemia and reperfusion injury.
    J Hepatol. 2014;60:1032-9.
    PubMed     Text format     Abstract available


  442. TACKE F, Zimmermann HW
    Macrophage heterogeneity in liver injury and fibrosis.
    J Hepatol. 2014;60:1090-6.
    PubMed     Text format     Abstract available


  443. DE LEDINGHEN V, Vergniol J, Capdepont M, Chermak F, et al
    Controlled attenuation parameter (CAP) for the diagnosis of steatosis: a prospective study of 5323 examinations.
    J Hepatol. 2014;60:1026-31.
    PubMed     Text format     Abstract available


  444. ASRANI SK, Talwalkar JA, Kamath PS, Shah VH, et al
    Role of magnetic resonance elastography in compensated and decompensated liver disease.
    J Hepatol. 2014;60:934-9.
    PubMed     Text format     Abstract available


    April 2014
  445. HYYSALO J, Mannisto VT, Zhou Y, Arola J, et al
    A population-based study on the prevalence of NASH using scores validated against liver histology.
    J Hepatol. 2014;60:839-46.
    PubMed     Text format     Abstract available


  446. MOLES A, Murphy L, Wilson CL, Chakraborty JB, et al
    A TLR2/S100A9/CXCL-2 signaling network is necessary for neutrophil recruitment in acute and chronic liver injury in the mouse.
    J Hepatol. 2014;60:782-91.
    PubMed     Text format     Abstract available


  447. LEUNG C, Herath CB, Jia Z, Goodwin M, et al
    Dietary glycotoxins exacerbate progression of experimental fatty liver disease.
    J Hepatol. 2014;60:832-8.
    PubMed     Text format     Abstract available


  448. MORELL CM, Strazzabosco M
    Notch signaling and new therapeutic options in liver disease.
    J Hepatol. 2014;60:885-90.
    PubMed     Text format     Abstract available


  449. FRANKO A, von Kleist-Retzow JC, Neschen S, Wu M, et al
    Liver adapts mitochondrial function to insulin resistant and diabetic states in mice.
    J Hepatol. 2014;60:816-23.
    PubMed     Text format     Abstract available


  450. ABRIGO JM, Shen J, Wong VW, Yeung DK, et al
    Non-alcoholic fatty liver disease: spectral patterns observed from an in vivo phosphorus magnetic resonance spectroscopy study.
    J Hepatol. 2014;60:809-15.
    PubMed     Text format     Abstract available


    December 2013
  451. FAGIUOLI S, Colli A, Bruno R, Craxi A, et al
    Management of infections pre- and post-liver transplantation: Report of a AISF Consensus Conference.
    J Hepatol. 2013 Dec 30. pii: S0168-8278(13)00890.
    PubMed     Text format     Abstract available


  452. SENKERIKOVA R, Mare-Bredemeijer ED, Frankova S, Roelen D, et al
    Genetic variation in TNFA predicts protection from severe bacterial infections in patients with end-stage liver disease awaiting liver transplantation.
    J Hepatol. 2013 Dec 18. pii: S0168-8278(13)00879.
    PubMed     Text format     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Liver Diseases is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: